|
US5945098A
(en)
|
1990-02-01 |
1999-08-31 |
Baxter International Inc. |
Stable intravenously-administrable immune globulin preparation
|
|
US5919452A
(en)
|
1991-03-18 |
1999-07-06 |
New York University |
Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
|
|
US5698195A
(en)
|
1991-03-18 |
1997-12-16 |
New York University Medical Center |
Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
|
|
US5656272A
(en)
|
1991-03-18 |
1997-08-12 |
New York University Medical Center |
Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
|
|
US6277969B1
(en)
|
1991-03-18 |
2001-08-21 |
New York University |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
|
US7192584B2
(en)
|
1991-03-18 |
2007-03-20 |
Centocor, Inc. |
Methods of treating psoriasis with anti-TNF antibodies
|
|
US6284471B1
(en)
|
1991-03-18 |
2001-09-04 |
New York University Medical Center |
Anti-TNFa antibodies and assays employing anti-TNFa antibodies
|
|
US6270766B1
(en)
|
1992-10-08 |
2001-08-07 |
The Kennedy Institute Of Rheumatology |
Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
|
|
ATE226090T1
(de)
|
1994-04-22 |
2002-11-15 |
Yamanouchi Pharma Co Ltd |
Kolon-spezifisches arzneistofffreisetzungssystem
|
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
|
ATE239041T1
(de)
|
1996-02-09 |
2003-05-15 |
Basf Ag |
Humane antikörper welche an humanen tnfalpha binden
|
|
GB9610992D0
(en)
|
1996-05-24 |
1996-07-31 |
Glaxo Group Ltd |
Concentrated antibody preparation
|
|
JP2000516594A
(ja)
|
1996-07-26 |
2000-12-12 |
スミスクライン・ビーチャム・コーポレイション |
免疫細胞介在全身性疾患の改良された治療法
|
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
|
ES2179414T3
(es)
|
1997-11-22 |
2003-01-16 |
Roche Diagnostics Gmbh |
Procedimiento mejorado de estabilizacion de proteinas.
|
|
EP1043031A4
(fr)
|
1997-12-26 |
2007-05-02 |
Astellas Pharma Inc |
Compositions medicinales a liberation prolongee
|
|
DE19814084B4
(de)
|
1998-03-30 |
2005-12-22 |
Lts Lohmann Therapie-Systeme Ag |
D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
|
|
DK2270044T3
(en)
|
1998-06-09 |
2015-01-26 |
Csl Behring Ag |
Liquid immunoglobulin G (IgG) product
|
|
GB9812545D0
(en)
|
1998-06-10 |
1998-08-05 |
Celltech Therapeutics Ltd |
Biological products
|
|
HK1041264B
(zh)
|
1998-07-23 |
2007-08-17 |
安斯泰来制药有限公司 |
咪唑化合物及其作为腺苷脱氨酶抑制剂的用途
|
|
GB9824632D0
(en)
|
1998-11-10 |
1999-01-06 |
Celltech Therapeutics Ltd |
Biological compounds
|
|
DK1142905T3
(da)
|
1999-01-13 |
2006-09-18 |
Astellas Pharma Inc |
Hidtil ukendt depsipeptidforbindelse
|
|
BR0009323A
(pt)
|
1999-03-25 |
2002-01-08 |
Knoll Gmbh |
Anticorpos humanos que ligam a il-12 humana e métodos para a produção
|
|
ES2338210T3
(es)
|
1999-11-11 |
2010-05-05 |
Astellas Pharma Inc. |
Metaloproteasa novedosa que tiene actividad agrecanasa.
|
|
DE60029624T2
(de)
|
1999-12-22 |
2007-08-09 |
Ucb S.A. |
Homologe enzyme der humanen heparanase sowie alternative spleissformen davon
|
|
EP1259604A1
(fr)
|
2000-02-25 |
2002-11-27 |
Oxford GlycoSciences (UK) Limited |
Proteine bcmp 84 associee au cancer du sein
|
|
DE60130910T2
(de)
|
2000-04-17 |
2008-07-10 |
Ucb Pharma, S.A. |
Enamin-derivate als zell-adhäsionsmoleküle
|
|
JP2001322933A
(ja)
|
2000-05-15 |
2001-11-20 |
Ucb Sa |
Cd40シグナル遮断剤
|
|
GB0013810D0
(en)
|
2000-06-06 |
2000-07-26 |
Celltech Chiroscience Ltd |
Biological products
|
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
|
ES2288909T3
(es)
|
2000-12-18 |
2008-02-01 |
Astellas Pharma Inc. |
Nueva agrecanasa.
|
|
WO2002053544A1
(fr)
|
2000-12-29 |
2002-07-11 |
Darwin Discovery Ltd. |
Utilisations pharmaceutiques et synthese de nicotinanilide-n-oxydes
|
|
US20140186361A1
(en)
|
2012-09-07 |
2014-07-03 |
Coherus Biosciences, Inc. |
Stable Aqueous Formulations of Adalimumab
|
|
CA2817619A1
(fr)
|
2001-06-08 |
2002-12-08 |
Abbott Laboratories (Bermuda) Ltd. |
Methodes pour administrer des anticorps anti-tnf.alpha.
|
|
GB0114644D0
(en)
|
2001-06-15 |
2001-08-08 |
Oxford Glycosciences Uk Ltd |
Protein
|
|
KR20040010713A
(ko)
|
2001-06-15 |
2004-01-31 |
야마노우치세이야쿠 가부시키가이샤 |
페닐피리딘 카보닐 피페라진 유도체
|
|
TR201809678T4
(tr)
|
2001-06-26 |
2018-07-23 |
Amgen Fremont Inc |
Opgl ye karşi antikorlar.
|
|
AU2002320352A1
(en)
|
2001-07-24 |
2003-02-17 |
Biogen Idec Ma Inc. |
Methods for treating or preventing sclerotic disorders using cd2-binding agents
|
|
TWI327597B
(en)
|
2001-08-01 |
2010-07-21 |
Centocor Inc |
Anti-tnf antibodies, compositions, methods and uses
|
|
US20030224345A1
(en)
|
2001-08-24 |
2003-12-04 |
Advanced Cell Technology |
Screening assays for identifying differentiation-inducing agents and production of differentiated cells for cell therapy
|
|
RU2305111C2
(ru)
|
2001-09-25 |
2007-08-27 |
Джуридикэл Фаундейшн Дзе Чемо-Серо-Терапьютик Рисерч Инститьют |
Рекомбинантное антитело против остеопонтина и его применение
|
|
US20030138417A1
(en)
|
2001-11-08 |
2003-07-24 |
Kaisheva Elizabet A. |
Stable liquid pharmaceutical formulation of IgG antibodies
|
|
NZ533240A
(en)
|
2001-11-27 |
2007-12-21 |
Oxford Glycosciences Uk Ltd |
Use of polypeptide for the treatment of epithelial-derived cancer
|
|
US7261892B2
(en)
|
2001-11-27 |
2007-08-28 |
Celltech R&D Limited |
Methods for diagnosis and treatment of epithelial-derived cancers
|
|
GB0129105D0
(en)
|
2001-12-05 |
2002-01-23 |
Celltech R&D Ltd |
Expression control using variable intergenic sequences
|
|
GB0207533D0
(en)
|
2002-04-02 |
2002-05-08 |
Oxford Glycosciences Uk Ltd |
Protein
|
|
GB0208089D0
(en)
|
2002-04-09 |
2002-05-22 |
Oxford Glycosciences Uk Ltd |
Protein
|
|
WO2003093237A1
(fr)
|
2002-04-30 |
2003-11-13 |
Ucb, S.A. |
Derives de 2,6-quinolinyle et de 2,6-naphtyle, leurs procedes de preparation et leur utilisation comme inhibiteurs de vla-4
|
|
JP4418745B2
(ja)
|
2002-05-28 |
2010-02-24 |
ユセベ ファルマ ソシエテ アノニム |
抗体peg位置異性体、それを含む組成物及びその使用
|
|
US7186511B2
(en)
|
2002-06-06 |
2007-03-06 |
Astellas Pharma Inc. |
Oxidase
|
|
GB0214268D0
(en)
|
2002-06-20 |
2002-07-31 |
Celltech R&D Ltd |
Chemical compounds
|
|
EP1521581B1
(fr)
|
2002-07-02 |
2008-02-20 |
UCB Farchim S.A. |
Diarylmethylpiperazines utiles comme agents prophylactiques ou therapeutiques de la myocardite virale
|
|
US20040131614A1
(en)
|
2002-07-19 |
2004-07-08 |
Abbott Biotechnology Ltd. |
Treatment of pulmonary disorders using TNFalpha inhibitor
|
|
GB0218800D0
(en)
|
2002-08-13 |
2002-09-18 |
Celltech R&D Ltd |
Chemical compounds
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
GB0222743D0
(en)
|
2002-10-01 |
2002-11-06 |
Celltech R&D Ltd |
Chemical compounds
|
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
|
EP1572976B1
(fr)
|
2002-11-21 |
2010-09-15 |
Celltech R & D, Inc. |
Modulation de reponses immunitaires
|
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
|
PL378245A1
(pl)
|
2003-01-09 |
2006-03-20 |
Astellas Pharma Inc. |
Pochodne pirolopirydazyny
|
|
US7335689B2
(en)
|
2003-01-23 |
2008-02-26 |
Esperion Therapeutics, Inc. |
Dihydroxyl compounds and compositions for cholesterol management and related uses
|
|
AU2004212942A1
(en)
|
2003-02-14 |
2004-09-02 |
Depuy Spine, Inc. |
In-situ formed intervertebral fusion device
|
|
WO2004074478A1
(fr)
|
2003-02-19 |
2004-09-02 |
Astellas Pharma Inc. |
Procede d'evaluation de l'effet antitumoral d'un inhibiteur d'histone desacetylase
|
|
US6805686B1
(en)
|
2003-05-06 |
2004-10-19 |
Abbott Laboratories |
Autoinjector with extendable needle protector shroud
|
|
EP1481683A1
(fr)
|
2003-05-30 |
2004-12-01 |
Yamanouchi Pharmaceutical Co. Ltd. |
Ligands ayant pour cible la P-selectine et compositions les comprenant
|
|
GB0312481D0
(en)
|
2003-05-30 |
2003-07-09 |
Celltech R&D Ltd |
Antibodies
|
|
AU2004249495A1
(en)
|
2003-06-20 |
2004-12-29 |
Ucb Pharma S.A. |
Thienopyridone derivatives as kinase inhibitors
|
|
CA2528603A1
(fr)
|
2003-06-20 |
2004-12-29 |
Celltech R & D Limited |
Derives de thienopyridone en tant qu'inhibiteurs de kinase
|
|
PT1644412E
(pt)
|
2003-07-01 |
2015-12-23 |
Ucb Biopharma Sprl |
Fragmentos de anticorpos fab modificados
|
|
JPWO2005002590A1
(ja)
|
2003-07-01 |
2006-08-10 |
アステラス製薬株式会社 |
骨量増加誘導剤
|
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
|
WO2005042540A1
(fr)
|
2003-10-24 |
2005-05-12 |
Celltech R & D Limited |
Utilisation de derives de thieno-pyridonone comme inhibiteurs de kinases
|
|
GB0325836D0
(en)
|
2003-11-05 |
2003-12-10 |
Celltech R&D Ltd |
Biological products
|
|
PL1685849T3
(pl)
|
2003-11-20 |
2012-07-31 |
Astellas Pharma Inc |
Inhibitory PDE 4 do leczenia śródmiąższowego zapalenia pęcherza moczowego
|
|
EP1983000B1
(fr)
|
2003-11-21 |
2015-09-02 |
UCB Biopharma SPRL |
Procédé pour le traitement de la sclérose en plaque par l'inhibition d'activité IL-17
|
|
DOP2005000002A
(es)
|
2004-01-09 |
2005-08-15 |
Pfizer |
"anticuerpos contra madcam"
|
|
JP2007104902A
(ja)
|
2004-01-16 |
2007-04-26 |
Astellas Pharma Inc |
関節リウマチ治療薬のスクリーニング法
|
|
JP2007104901A
(ja)
|
2004-01-16 |
2007-04-26 |
Astellas Pharma Inc |
関節リウマチ治療薬のスクリーニング法
|
|
US20190282622A1
(en)
|
2004-01-23 |
2019-09-19 |
Astellas Institute For Regenerative Medicine |
Modalities for the treatment of degenerative diseases of the retina
|
|
US7670624B2
(en)
|
2004-01-29 |
2010-03-02 |
Astella Pharma Inc. |
Gastrointestinal-specific multiple drug release system
|
|
TWI439284B
(zh)
|
2004-04-09 |
2014-06-01 |
艾伯維生物技術有限責任公司 |
用於治療TNFα相關失調症之多重可變劑量療法
|
|
KR20070012407A
(ko)
|
2004-04-15 |
2007-01-25 |
아스텔라스세이야쿠 가부시키가이샤 |
2-아미노피리미딘 유도체
|
|
GB0411186D0
(en)
|
2004-05-19 |
2004-06-23 |
Celltech R&D Ltd |
Biological products
|
|
GB0412181D0
(en)
|
2004-06-01 |
2004-06-30 |
Celltech R&D Ltd |
Biological products
|
|
JP2007277093A
(ja)
|
2004-06-21 |
2007-10-25 |
Astellas Pharma Inc |
三環系化合物
|
|
JP2007269629A
(ja)
|
2004-06-21 |
2007-10-18 |
Astellas Pharma Inc |
キナゾリン誘導体
|
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
|
ATE415400T1
(de)
|
2004-07-05 |
2008-12-15 |
Astellas Pharma Inc |
Pyrazolopyridinderivate
|
|
WO2006004191A1
(fr)
|
2004-07-05 |
2006-01-12 |
Astellas Pharma Inc. |
Derivés de pyrrolopyridazine qui inhibent la pde iv et le tnf alpha
|
|
WO2006038734A1
(fr)
|
2004-10-08 |
2006-04-13 |
Astellas Pharma Inc. |
Dérivés de la pyridazinone inhibiteurs de cytokines
|
|
US7893315B2
(en)
|
2004-11-04 |
2011-02-22 |
Advanced Cell Technology, Inc. |
Derivation of embryonic stem cells and embryo-derived cells
|
|
GB0425569D0
(en)
|
2004-11-19 |
2004-12-22 |
Celltech R&D Ltd |
Biological products
|
|
GB0425972D0
(en)
|
2004-11-25 |
2004-12-29 |
Celltech R&D Ltd |
Biological products
|
|
CA2591813A1
(fr)
|
2004-12-21 |
2006-06-29 |
Centocor, Inc. |
Anticorps anti-il-12, epitopes, compositions, procedes et utilisations associes
|
|
JP2008529968A
(ja)
|
2005-02-08 |
2008-08-07 |
国立循環器病センター総長 |
インスリン様成長因子−1(igf−1)を使用する慢性重症心不全を処置するための新規方法
|
|
JP4895219B2
(ja)
|
2005-02-16 |
2012-03-14 |
アステラス製薬株式会社 |
Rock阻害剤を含有する疼痛治療剤
|
|
GB0506912D0
(en)
|
2005-04-05 |
2005-05-11 |
Celltech R&D Ltd |
Biological products
|
|
JP5757495B2
(ja)
|
2005-05-16 |
2015-07-29 |
アッヴィ バイオテクノロジー リミテッド |
びらん性多発性関節炎の治療のためのtnf阻害剤の使用
|
|
CA2610800A1
(fr)
|
2005-06-09 |
2006-12-14 |
Ucb Pharma, S.A. |
Derives de 2,6-quinolinyle, procedes d'elaboration et leur utilisation comme medicaments
|
|
JP2008543839A
(ja)
|
2005-06-14 |
2008-12-04 |
アムジェン インコーポレーテッド |
自己緩衝タンパク質製剤
|
|
CA2613818C
(fr)
|
2005-06-30 |
2013-08-27 |
Centocor, Inc. |
Anticorps anti-il-23, compositions, methodes et utilisations
|
|
GB0513852D0
(en)
|
2005-07-06 |
2005-08-10 |
Celltech R&D Ltd |
Biological products
|
|
GB0514779D0
(en)
|
2005-07-19 |
2005-08-24 |
Celltech R&D Ltd |
Biological products
|
|
ES2933478T3
(es)
|
2005-08-03 |
2023-02-09 |
Astellas Inst For Regenerative Medicine |
Métodos mejorados de reprogramación de células somáticas animales
|
|
ES2336605T3
(es)
|
2005-08-12 |
2010-04-14 |
Astellas Pharma Inc. |
Metodo para identificar la proteina diana de un agente y metodo para explorar un agente terapeutico para diabetes usando la proteina diana.
|
|
EP1754476A1
(fr)
|
2005-08-18 |
2007-02-21 |
Schwarz Pharma Ag |
Lacosamide (SPM 927) pour le traitement de la myalgie, par exemple de la fibromyalgie
|
|
TW200745034A
(en)
|
2005-09-01 |
2007-12-16 |
Astellas Pharma Inc |
New compounds
|
|
WO2007031734A1
(fr)
|
2005-09-14 |
2007-03-22 |
Ucb Pharma S.A. |
Polymères à structure en peigne
|
|
GB0520169D0
(en)
|
2005-10-04 |
2005-11-09 |
Celltech R&D Ltd |
Biological products
|
|
TW201337266A
(zh)
|
2005-11-01 |
2013-09-16 |
Abbott Biotech Ltd |
利用生物標記診斷關節黏連脊椎炎之方法及組合物
|
|
GB0523954D0
(en)
|
2005-11-24 |
2006-01-04 |
Ucb Celltech |
Bioassays
|
|
WO2007060411A1
(fr)
|
2005-11-24 |
2007-05-31 |
Ucb Pharma S.A. |
Anticorps anti-tnf alpha qui inhibent sélectivement le signal tnf alpha par le p55r
|
|
EP1790664A1
(fr)
|
2005-11-24 |
2007-05-30 |
Ganymed Pharmaceuticals AG |
Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
|
|
CA2632628C
(fr)
|
2005-12-09 |
2016-01-19 |
Ucb Pharma S.A. |
Molecules d'anticorps ayant une specificite pour l'il-6 humaine
|
|
CN102391358B
(zh)
|
2006-04-05 |
2016-08-10 |
艾伯维生物技术有限公司 |
抗体纯化
|
|
WO2008063213A2
(fr)
|
2006-04-10 |
2008-05-29 |
Abbott Biotechnology Ltd. |
Compositions destinées au traitement de la polyarthrite psoriasique et leurs applications
|
|
US9605064B2
(en)
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
|
WO2007120626A2
(fr)
|
2006-04-10 |
2007-10-25 |
Abbott Biotechnology Ltd. |
Utilisations et compositions pour le traitement de la spondylarthrite ankylosante
|
|
US9399061B2
(en)
|
2006-04-10 |
2016-07-26 |
Abbvie Biotechnology Ltd |
Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
|
|
AU2007238660C1
(en)
|
2006-04-14 |
2013-11-07 |
Astellas Institute For Regenerative Medicine |
Hemangio-colony forming cells
|
|
US8808707B1
(en)
|
2006-05-08 |
2014-08-19 |
Wyeth Llc |
Pneumococcal dosing regimen
|
|
BRPI0711229A2
(pt)
|
2006-05-31 |
2013-01-08 |
Astellas Pharma Inc |
anticorpo humanizado da osteopontina anti-humana, polinucleotÍdeo, vetor de expressço, cÉlula hospedeita, mÉtodo para produzir um anticorpo humanizado de osteopontina anti-humana, fÁrmaco terapÊutico, mÉtodo para prevenir ou tratar doenÇa autoimune e uso do anticorpo humanizado de oesteopontina anti-humana
|
|
US20100021451A1
(en)
|
2006-06-08 |
2010-01-28 |
Wong Robert L |
Uses and compositions for treatment of ankylosing spondylitis
|
|
CA2652667A1
(fr)
|
2006-06-08 |
2007-12-13 |
Schwarz Pharma Ag |
Combinaison therapeutique pour etats medicaux douloureux
|
|
TWI392670B
(zh)
|
2006-06-22 |
2013-04-11 |
Ucb Pharma Gmbh |
經取代的2-胺基萘滿之於製造用於預防、減緩及/或治療各種類型疼痛之藥物上的用途
|
|
GB0612928D0
(en)
|
2006-06-29 |
2006-08-09 |
Ucb Sa |
Biological products
|
|
CN103316402A
(zh)
|
2006-06-30 |
2013-09-25 |
艾伯维生物技术有限公司 |
自动注射装置
|
|
GB0613209D0
(en)
|
2006-07-03 |
2006-08-09 |
Ucb Sa |
Methods
|
|
AU2007279092B2
(en)
|
2006-07-24 |
2012-12-13 |
Ucb Pharma S.A. |
Substituted aniline derivatives
|
|
GB0614780D0
(en)
|
2006-07-25 |
2006-09-06 |
Ucb Sa |
Biological products
|
|
DK2061897T3
(da)
|
2006-07-27 |
2020-06-02 |
Wyeth Llc |
Fed-batch-fermenteringsproces med høj celledensitet til fremstilling af rekombinant protein
|
|
WO2008026781A1
(fr)
|
2006-08-31 |
2008-03-06 |
Astellas Pharma Inc. |
Vésicule de lipide à ciblage inverse
|
|
EP2066645A2
(fr)
|
2006-09-12 |
2009-06-10 |
UCB Pharma S.A. |
Dérivés de 2 amino-pyrimidine en tant qu'antagonistes des récepteurs h4, leurs procédés de préparation et leur utilisation dans des compositions pharmaceutiques
|
|
US8911964B2
(en)
|
2006-09-13 |
2014-12-16 |
Abbvie Inc. |
Fed-batch method of making human anti-TNF-alpha antibody
|
|
TW201516149A
(zh)
|
2006-09-13 |
2015-05-01 |
Abbvie Inc |
細胞培養改良
|
|
MX2009003398A
(es)
|
2006-09-27 |
2009-08-12 |
Coley Pharm Gmbh |
Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
|
|
GB0619291D0
(en)
|
2006-09-29 |
2006-11-08 |
Ucb Sa |
Altered antibodies
|
|
US10068220B2
(en)
|
2006-10-11 |
2018-09-04 |
Visa International Service Association |
Systems and methods for brokered authentication express seller links
|
|
GB0620729D0
(en)
|
2006-10-18 |
2006-11-29 |
Ucb Sa |
Biological products
|
|
EP2684895A1
(fr)
|
2006-10-27 |
2014-01-15 |
AbbVie Biotechnology Ltd |
Anticorps anti-hTNfalpha cristallins
|
|
WO2008064830A1
(fr)
|
2006-11-27 |
2008-06-05 |
Ucb Pharma, S.A. |
Dérivés bicycliques et hétérobicycliques, leurs procédés de fabrication et leurs utilisations pharmaceutiques
|
|
WO2008064823A1
(fr)
|
2006-11-27 |
2008-06-05 |
Ucb Pharma, S.A. |
Dérivés bicycliques et hétérobicycliques, procédés de préparation de ceux-ci et leurs utilisations
|
|
WO2008064829A2
(fr)
|
2006-11-30 |
2008-06-05 |
Ucb Pharma, S.A. |
Nouveaux dérivés d'aminothiénopyridinone, procédés de préparation de ces dérivés et compositions pharmaceutiques à base de ceux-ci
|
|
WO2008074445A1
(fr)
|
2006-12-18 |
2008-06-26 |
Ucb Pharma, S.A. |
Nouveaux dérivés tricycliques et hétérocycliques, procédés destinés à les préparer et compositions pharmaceutiques les contenant
|
|
ES2474940T3
(es)
|
2006-12-28 |
2014-07-10 |
Janssen Biotech, Inc. |
Métodos y vectores que generan inmunoglobulinas sialiladas
|
|
WO2008092084A2
(fr)
|
2007-01-26 |
2008-07-31 |
Centocor, Inc. |
Suspension non aqueuse injectable présentant une concentration élevée en agent thérapeutique
|
|
KR20100014504A
(ko)
|
2007-02-23 |
2010-02-10 |
어드밴스드 셀 테크놀로지, 인코포레이티드 |
분화된 세포를 리프로그래밍하고, 리프로그래밍된 세포로부터 동물 및 배아 줄기세포를 생성시키기 위한 고도로 효율적인 방법
|
|
US8147833B2
(en)
|
2007-02-23 |
2012-04-03 |
Neotope Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
|
BRPI0809042B1
(pt)
|
2007-03-22 |
2021-08-31 |
Biogen Ma Inc. |
Proteína de ligação a cd154 isolada, seu uso, e composição
|
|
WO2008121324A2
(fr)
|
2007-03-30 |
2008-10-09 |
Abbott Laboratories |
Eléments de vecteurs d'expression recombinants (reve) destinés à augmenter l'expression de protéines recombinantes dans des cellules hôtes
|
|
WO2008122378A1
(fr)
|
2007-04-04 |
2008-10-16 |
Ucb Pharma, S.A. |
Nouveaux derives de pyridine, procedes de preparation et compositions pharmaceutiques associes
|
|
WO2008125215A1
(fr)
|
2007-04-12 |
2008-10-23 |
Ucb Pharma, S.A. |
Dérivés bicycliques et hétérobicycliques, procédés de préparation et utilisations de ceux-ci
|
|
WO2008125210A1
(fr)
|
2007-04-12 |
2008-10-23 |
Ucb Pharma, S.A. |
Dérivés de quinoline et de naphtalène, procédés de préparation et utilisation de ceux-ci pour traiter des maladies inflammatoires
|
|
TW200904421A
(en)
|
2007-05-03 |
2009-02-01 |
Astellas Pharma Inc |
New compounds
|
|
WO2008138591A2
(fr)
|
2007-05-14 |
2008-11-20 |
Ucb Pharma, S.A. |
Dérivés bicycliques et hétérobicycliques, leurs méthodes de préparation et leurs utilisations
|
|
WO2008138592A1
(fr)
|
2007-05-14 |
2008-11-20 |
Ucb Pharma, S.A. |
Dérivés bicycliques et hétérobicycliques, leurs méthodes de préparation et leurs utilisations
|
|
WO2008138615A1
(fr)
|
2007-05-16 |
2008-11-20 |
Ucb Pharma, S.A. |
Dérivés bicycliques et hétérobicycliques, leurs méthodes de préparation et leurs utilisations
|
|
EP1997832A1
(fr)
|
2007-05-29 |
2008-12-03 |
Ganymed Pharmaceuticals AG |
Anticorps monoclonaux contre la claudine-18 pour le traitement contre le cancer
|
|
EP2165194A4
(fr)
|
2007-05-31 |
2010-09-08 |
Abbott Lab |
BIOMARQUEURS PRÉDICTIFS DE LA RÉACTIVITÉ AUX INHIBITEURS TNF-alpha DANS DES TROUBLES AUTO-IMMUNS
|
|
WO2008149965A1
(fr)
|
2007-06-07 |
2008-12-11 |
Astellas Pharma Inc. |
Composé de pyridone
|
|
SG182183A1
(en)
|
2007-06-08 |
2012-07-30 |
Biogen Idec Inc |
Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
|
|
EP2171451A4
(fr)
|
2007-06-11 |
2011-12-07 |
Abbott Biotech Ltd |
Procédés de traitement de l'arthrite idiopathique juvénile
|
|
MX2010001488A
(es)
|
2007-08-08 |
2010-03-01 |
Abbott Lab |
Composiciones y metodos para cristalizar anticuerpos.
|
|
WO2009032128A1
(fr)
|
2007-08-28 |
2009-03-12 |
Abbott Biotechnology Ltd. |
Compositions et procédés comprenant des protéines de liaison pour adalimumab
|
|
EP2535350B1
(fr)
|
2007-09-26 |
2018-01-24 |
UCB Biopharma SPRL |
Fusions d'anticorps à double spécificité
|
|
WO2009047255A1
(fr)
|
2007-10-09 |
2009-04-16 |
Ucb Pharma, S.A. |
Composés hétérobicycliques utiles comme antagonistes du récepteur h4 de l'histamine
|
|
EP2209888B1
(fr)
|
2007-10-12 |
2019-12-04 |
Astellas Institute for Regenerative Medicine |
Procédés améliorés pour la production de cellules rpe et de compositions de cellules rpe
|
|
CA2703263C
(fr)
|
2007-11-01 |
2014-03-18 |
Perseid Therapeutics Llc |
Polypeptide immunosuppresseur et acides nucleiques
|
|
WO2009059235A2
(fr)
|
2007-11-01 |
2009-05-07 |
Facet Biotech Corporation |
Vecteurs de présentation d'immunoglobulines
|
|
US8420081B2
(en)
|
2007-11-30 |
2013-04-16 |
Abbvie, Inc. |
Antibody formulations and methods of making same
|
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
|
SI2242771T1
(sl)
|
2007-12-14 |
2013-09-30 |
Bristol-Myers Squibb Company |
Vezane molekule k humanemu ox40 receptorju
|
|
ES2579231T3
(es)
|
2008-01-15 |
2016-08-08 |
Abbvie Inc |
Vectores de expresión de mamíferos mejorados y usos de los mismos
|
|
ES2523169T3
(es)
|
2008-01-25 |
2014-11-21 |
High Point Pharmaceuticals, Llc |
Compuestos tricíclicos como moduladores de la síntesis de TNF y como inhibidores de PDE4
|
|
GB0807413D0
(en)
|
2008-04-23 |
2008-05-28 |
Ucb Pharma Sa |
Biological products
|
|
US20110086424A1
(en)
|
2008-05-06 |
2011-04-14 |
Advanced Cell Technology, Inc. |
Methods for producing enucleated erythroid cells derived from pluripotent stem cells
|
|
BRPI0912201A2
(pt)
|
2008-05-06 |
2019-09-24 |
Advanced Cell Tech Inc |
células formadoras de colônias de hemangios e células de hemangio não enxertantes
|
|
ES2518919T3
(es)
|
2008-05-14 |
2014-11-05 |
Astellas Pharma Inc. |
Derivados del ácido 4-(Indol-7-ilcarbonilaminometil)ciclohexanocarboxílico como antagonistas del receptor EP4 útiles para el tratamiento de la insuficiencia renal crónica o la nefropatía diabética
|
|
CN102119031B
(zh)
|
2008-06-11 |
2014-09-10 |
弗雷森纽斯医疗护理德国有限责任公司 |
肝祖细胞的条件培养基
|
|
EP2301922A4
(fr)
|
2008-06-17 |
2012-06-06 |
Astellas Pharma Inc |
Composé pyridone
|
|
ES2569907T3
(es)
|
2008-06-27 |
2016-05-13 |
Zoetis Services Llc |
Composiciones adyuvantes novedosas
|
|
DK2326371T3
(da)
|
2008-07-18 |
2019-11-18 |
Ucb Biopharma Sprl |
Systemer til indgift af medicin til patienter med rheumatoid arthritis
|
|
EP2166021A1
(fr)
|
2008-09-16 |
2010-03-24 |
Ganymed Pharmaceuticals AG |
Anticorps monoclonaux pour le traitement du cancer
|
|
US10407513B2
(en)
|
2008-09-26 |
2019-09-10 |
Ucb Biopharma Sprl |
Biological products
|
|
CN104974251A
(zh)
|
2008-10-20 |
2015-10-14 |
Abbvie公司 |
在抗体纯化过程中的病毒灭活
|
|
CA2932207A1
(fr)
|
2008-10-20 |
2010-12-09 |
Abbvie Inc. |
Isolation et purification d'anticorps au moyen de chromatographie d'affinite de proteine a
|
|
WO2010051032A1
(fr)
|
2008-10-31 |
2010-05-06 |
Synthes Usa, Llc |
Méthode et dispositif d’activation de cellules souches
|
|
KR101689688B1
(ko)
|
2008-11-18 |
2016-12-26 |
유씨비 파마, 에스.에이. |
2옥소1피롤리딘 유도체를 포함하는 지연 방출형 제형
|
|
EP2327299B8
(fr)
|
2008-12-16 |
2012-06-27 |
Astellas Pharma Inc. |
Rongeur modèle de douleur musculaire chronique
|
|
AU2010216152B2
(en)
|
2009-02-17 |
2015-05-14 |
Ucb Biopharma Sprl |
Antibody molecules having specificity for human OX40
|
|
GB0904214D0
(en)
|
2009-03-11 |
2009-04-22 |
Ucb Pharma Sa |
Biological products
|
|
US8871220B2
(en)
|
2009-04-03 |
2014-10-28 |
Merial Limited |
Newcastle disease virus vectored avian vaccines
|
|
RU2595379C2
(ru)
|
2009-04-16 |
2016-08-27 |
АббВай Биотерапеутикс Инк. |
АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ
|
|
AU2010242972B2
(en)
|
2009-04-29 |
2015-07-09 |
Abbvie Biotechnology Ltd |
Automatic injection device
|
|
JP2012197228A
(ja)
|
2009-07-27 |
2012-10-18 |
Kyoto Univ |
肝炎の治療剤もしくは予防剤
|
|
WO2011030107A1
(fr)
|
2009-09-10 |
2011-03-17 |
Ucb Pharma S.A. |
Anticorps multivalents
|
|
US20110070227A1
(en)
|
2009-09-18 |
2011-03-24 |
Anna-Marie Novotney-Barry |
Treatment of Autoimmune and Inflammatory Diseases
|
|
WO2011036455A1
(fr)
|
2009-09-24 |
2011-03-31 |
Ucb Pharma S.A. |
Souche bactérienne pour l'expression de protéines recombinantes, ayant une degp à activité protéase déficiente et conservant une activité chaperonne et des gènes tsp et ptr inactivés
|
|
CA2774692C
(fr)
|
2009-09-24 |
2017-12-19 |
Ucb Pharma S.A. |
Souche bacterienne permettant l'expression de proteines recombinantes, presentant une degp protease-deficiente conservant une activite chaperonne, ainsi que des genes tsp et ptr inactives
|
|
GB201005063D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
|
JP2012254939A
(ja)
|
2009-10-07 |
2012-12-27 |
Astellas Pharma Inc |
オキサゾール化合物
|
|
GB0920127D0
(en)
|
2009-11-17 |
2009-12-30 |
Ucb Pharma Sa |
Antibodies
|
|
IL281453B
(en)
|
2009-11-17 |
2022-07-01 |
Astellas Inst For Regenerative Medicine |
Methods for preparing human rpe cells and pharmaceutical preparations of human rpe cells
|
|
GB0920324D0
(en)
|
2009-11-19 |
2010-01-06 |
Ucb Pharma Sa |
Antibodies
|
|
US9096879B2
(en)
|
2009-11-24 |
2015-08-04 |
Biogen Ma Inc. |
Method of supplementing culture media to prevent undesirable amino acid substitutions
|
|
WO2011071136A1
(fr)
|
2009-12-11 |
2011-06-16 |
アステラス製薬株式会社 |
Agent thérapeutique pour la fibromyalgie
|
|
EP2512558A4
(fr)
|
2009-12-15 |
2014-08-13 |
Abbvie Biotechnology Ltd |
Poussoir de déclenchement amélioré pour dispositif d'injection automatique
|
|
PL2513093T3
(pl)
|
2009-12-17 |
2015-03-31 |
Centrexion Therapeutics Corp |
Nowi antagoniści receptora CCR2 i ich zastosowanie
|
|
WO2011076879A1
(fr)
|
2009-12-22 |
2011-06-30 |
Ucb Pharma Gmbh |
Polyvinylpyrrolidone destinée à la stabilisation d'une dispersion solide de la forme non cristalline de la rotigotine
|
|
SG181628A1
(en)
|
2009-12-22 |
2012-07-30 |
Celldex Therapeutics Inc |
Vaccine compositions
|
|
GB201000467D0
(en)
|
2010-01-12 |
2010-02-24 |
Ucb Pharma Sa |
Antibodies
|
|
GB201000590D0
(en)
|
2010-01-14 |
2010-03-03 |
Ucb Pharma Sa |
Bacterial host strain
|
|
GB201000588D0
(en)
|
2010-01-14 |
2010-03-03 |
Ucb Pharma Sa |
Bacterial host strain
|
|
GB201000587D0
(en)
|
2010-01-14 |
2010-03-03 |
Ucb Pharma Sa |
Bacterial hoist strain
|
|
GB201000591D0
(en)
|
2010-01-14 |
2010-03-03 |
Ucb Pharma Sa |
Bacterial hoist strain
|
|
GB201001791D0
(en)
|
2010-02-03 |
2010-03-24 |
Ucb Pharma Sa |
Process for obtaining antibodies
|
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
|
CN102892786B
(zh)
|
2010-03-11 |
2016-03-16 |
Ucb医药有限公司 |
Pd-1抗体
|
|
EP2371864A1
(fr)
|
2010-03-23 |
2011-10-05 |
Ganymed Pharmaceuticals AG |
Anticorps monoclonaux pour le traitement du cancer
|
|
GB201005064D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
|
WO2011117653A1
(fr)
|
2010-03-25 |
2011-09-29 |
Ucb Pharma S.A. |
Molécules de dvd-lg stabilisées par un disulfure
|
|
EP2796467B1
(fr)
|
2010-03-31 |
2018-03-28 |
Boehringer Ingelheim International GmbH |
Anticorps anti-CD40
|
|
MX2012011629A
(es)
|
2010-04-07 |
2013-03-05 |
Abbvie Inc |
Proteinas de union a tnf-alfa.
|
|
JP5786020B2
(ja)
|
2010-04-16 |
2015-09-30 |
アボットジャパン株式会社 |
関節リウマチを診断する方法および試薬
|
|
KR102071212B1
(ko)
|
2010-04-21 |
2020-01-30 |
애브비 바이오테크놀로지 리미티드 |
치료제의 제어된 전달을 위한 착용형 자동 주사 디바이스
|
|
EP3943154A1
(fr)
|
2010-05-04 |
2022-01-26 |
Five Prime Therapeutics, Inc. |
Anticorps se liant au csf1r
|
|
CN102892791B
(zh)
|
2010-05-17 |
2017-05-17 |
Emd密理博公司 |
用于纯化生物分子的刺激响应性聚合物
|
|
HRP20181039T1
(hr)
|
2010-05-28 |
2018-08-24 |
Zoetis Belgium S.A. |
Cjepiva koja sadrže kolesterol i cpg kao jedine molekule koje nose adjuvans
|
|
MX2012014080A
(es)
|
2010-06-03 |
2013-05-01 |
Abbvie Biotechnology Ltd |
Usos y composiciones para el tratamiento de hidradenitis superativa (hs).
|
|
US8933228B2
(en)
|
2010-06-17 |
2015-01-13 |
Respivert, Ltd. |
Respiratory formulations and compounds for use therein
|
|
CN102946904A
(zh)
|
2010-06-18 |
2013-02-27 |
埃克斯生物科技公司 |
关节炎治疗
|
|
EP3875599B1
(fr)
|
2010-07-23 |
2024-12-11 |
Astellas Institute for Regenerative Medicine |
Procédés de détection de sous-populations rares de cellules et compositions de cellules très purifiées
|
|
GB201012603D0
(en)
|
2010-07-27 |
2010-09-08 |
Ucb Pharma Sa |
Protein purification
|
|
GB201012599D0
(en)
|
2010-07-27 |
2010-09-08 |
Ucb Pharma Sa |
Process for purifying proteins
|
|
GB201012784D0
(en)
|
2010-07-29 |
2010-09-15 |
Ucb Pharma Sa |
Method
|
|
GB201014033D0
(en)
|
2010-08-20 |
2010-10-06 |
Ucb Pharma Sa |
Biological products
|
|
KR101584871B1
(ko)
|
2010-09-10 |
2016-01-22 |
와이어쓰 엘엘씨 |
네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
|
|
JP2013249256A
(ja)
|
2010-09-15 |
2013-12-12 |
Astellas Pharma Inc |
脂肪性肝疾患治療薬
|
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
|
PH12013500703A1
(en)
|
2010-10-13 |
2013-05-20 |
Janssen Biotech Inc |
Human oncostatin m antibodies and methods of use
|
|
KR102049223B1
(ko)
|
2010-11-04 |
2019-11-28 |
베링거 인겔하임 인터내셔날 게엠베하 |
항-il-23 항체
|
|
TWI603739B
(zh)
|
2010-11-11 |
2017-11-01 |
艾伯維生物技術有限責任公司 |
具有增進高濃度之抗-TNFα抗體之液體調配物
|
|
EP2646001A2
(fr)
|
2010-12-02 |
2013-10-09 |
UCB Pharma GmbH |
Formulation de lacosamide
|
|
AR084210A1
(es)
|
2010-12-08 |
2013-05-02 |
Abbott Lab |
PROTEINAS DE UNION AL TNF-a
|
|
US10208349B2
(en)
|
2011-01-07 |
2019-02-19 |
Ucb Biopharma Sprl |
Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
|
|
PH12013501435B1
(en)
|
2011-01-14 |
2019-02-01 |
UCB Biopharma SRL |
Antibody molecules which bind il-17a and il-17f
|
|
SG192119A1
(en)
|
2011-01-24 |
2013-08-30 |
Abbvie Biotechnology Ltd |
Automatic injection devices having overmolded gripping surfaces
|
|
WO2012125553A2
(fr)
|
2011-03-12 |
2012-09-20 |
Momenta Pharmaceuticals, Inc. |
N-glycanes contenant de la n-acétylhexosamine dans des produits de glycoprotéines
|
|
TW201249867A
(en)
|
2011-04-01 |
2012-12-16 |
Astellas Pharma Inc |
Novel anti-human il-23 receptor antibody
|
|
WO2012149197A2
(fr)
|
2011-04-27 |
2012-11-01 |
Abbott Laboratories |
Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante
|
|
ES2776003T3
(es)
|
2011-05-27 |
2020-07-28 |
Boehringer Ingelheim Int |
Inhalador y cápsula para un inhalador
|
|
NZ618125A
(en)
|
2011-05-27 |
2016-03-31 |
Merial Ltd |
Genetic vaccines against hendra virus and nipah virus
|
|
WO2012164406A2
(fr)
|
2011-06-02 |
2012-12-06 |
Ucb Pharma S.A. |
Auto-injecteur
|
|
UY34105A
(es)
|
2011-06-03 |
2012-07-31 |
Lg Life Sciences Ltd |
Formulación líquida estable de etanercept
|
|
CN103717729B
(zh)
|
2011-07-08 |
2017-11-21 |
动量制药公司 |
细胞培养方法
|
|
CN103827134A
(zh)
|
2011-07-20 |
2014-05-28 |
泽普泰恩股份有限公司 |
多肽分离方法
|
|
CA2844927C
(fr)
|
2011-08-12 |
2017-10-31 |
Merial Limited |
Conservation sous vide de produits biologiques, et en particulier de vaccins
|
|
US9802954B2
(en)
|
2011-08-24 |
2017-10-31 |
Boehringer Ingelheim International Gmbh |
Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
|
|
ES2704632T3
(es)
|
2011-09-08 |
2019-03-19 |
Univ New York |
Virus de herpes simplex oncolítico y sus usos terapéuticos
|
|
CA2849806A1
(fr)
|
2011-09-22 |
2013-03-28 |
Abbvie Inc. |
Dispositif d'injection automatique
|
|
PT2750709T
(pt)
|
2011-09-23 |
2018-11-22 |
Xbiotech Inc |
Tratamento da caquexia
|
|
EP2578582A1
(fr)
|
2011-10-03 |
2013-04-10 |
Respivert Limited |
1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napthtalèn-1-yl) urées comme inhibiteurs de la p38 MAP kinase
|
|
PL2763984T3
(pl)
|
2011-10-03 |
2016-10-31 |
|
1-pirazolilo-3-(4-((2-anilinopirymidyno-4-ilo)oksy)naftaleno-1-ilo)moczniki jako inhibitory kinazy p38 MAP
|
|
US10485869B2
(en)
|
2011-10-18 |
2019-11-26 |
Coherus Biosciences, Inc. |
Etanercept formulations stabilized with meglumine
|
|
AU2012326170B2
(en)
|
2011-10-18 |
2016-12-22 |
Coherus Biosciences, Inc. |
Etanercept formulations stabilized with metal ions
|
|
AU2012328921B2
(en)
|
2011-10-24 |
2017-05-11 |
Abbvie Inc. |
Immunobinders directed against TNF
|
|
US20140288278A1
(en)
|
2011-10-31 |
2014-09-25 |
Joseph Nti-Gyabaah |
Chromatography process for resolving heterogeneous antibody aggregates
|
|
JP6411214B2
(ja)
|
2011-11-11 |
2018-10-24 |
ユーシービー バイオファルマ エスピーアールエル |
アルブミン結合抗体及びその結合断片
|
|
UA112203C2
(uk)
|
2011-11-11 |
2016-08-10 |
Юсб Фарма С.А. |
Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
|
|
IL287381B2
(en)
|
2011-11-14 |
2024-04-01 |
Astellas Inst For Regenerative Medicine |
Pharmaceutical preparations of human rpe cells and uses thereof
|
|
PL2785359T3
(pl)
|
2011-11-30 |
2018-12-31 |
Astellas Institute For Regenerative Medicine |
Mezenchymalne komórki zrębowe i związane z nimi zastosowania
|
|
US8961956B2
(en)
|
2011-11-30 |
2015-02-24 |
Ocata Therapeutics, Inc. |
Mesenchymal stromal cells and uses related thereto
|
|
DE102011087676A1
(de)
|
2011-12-02 |
2013-06-06 |
Continental Automotive Gmbh |
Verfahren und Vorrichtung zur Überprüfung einer Lautsprecheranordnung
|
|
US20130158077A1
(en)
|
2011-12-19 |
2013-06-20 |
Ares Trading S.A. |
Pharmaceutical compositions
|
|
GB201203071D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
|
GB201203051D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
|
US9371391B2
(en)
|
2012-02-28 |
2016-06-21 |
Astellas Pharma Inc. |
Anti-human IL-23 receptor antibody and encoding polynucleotides
|
|
PL2820640T3
(pl)
|
2012-03-02 |
2017-01-31 |
Abbvie Inc. |
Automatyczne szkoleniowe urządzenie wstrzykujące
|
|
KR20160105535A
(ko)
|
2012-03-07 |
2016-09-06 |
카딜라 핼쓰캐어 리미티드 |
TNF-α 항체의 약제학적 제형
|
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
|
JO3787B1
(ar)
|
2012-03-15 |
2021-01-31 |
Janssen Biotech Inc |
أجسام مضادة بشرية ضد cd27 و طرق و استخداماتها
|
|
KR102586316B1
(ko)
|
2012-03-22 |
2023-10-06 |
뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 |
개질된 마렉병 바이러스, 및 이로부터 제조된 백신
|
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
|
US9150645B2
(en)
|
2012-04-20 |
2015-10-06 |
Abbvie, Inc. |
Cell culture methods to reduce acidic species
|
|
CA2871793C
(fr)
|
2012-05-02 |
2020-09-15 |
Pharmaxis Ltd. |
Inhibiteurs de ssao 3-halogenoallylamines substituees et leurs utilisations
|
|
PL2844282T3
(pl)
|
2012-05-04 |
2019-11-29 |
Pfizer |
Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce
|
|
GB201208367D0
(en)
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Biological product
|
|
GB201208370D0
(en)
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Antibodies
|
|
WO2013174403A1
(fr)
|
2012-05-23 |
2013-11-28 |
Ganymed Pharmaceuticals Ag |
Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
|
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
|
CA2874303C
(fr)
|
2012-06-11 |
2020-10-13 |
Ucb Biopharma Sprl |
Benzimidazoles modulant l'activite tnf -alpha
|
|
EP2863951A1
(fr)
|
2012-06-12 |
2015-04-29 |
Boehringer Ingelheim International GmbH |
Formulation pharmaceutique destinée à un anticorps thérapeutique
|
|
CN104520326A
(zh)
|
2012-06-21 |
2015-04-15 |
Ucb医药有限公司 |
药物制剂
|
|
ES2689429T3
(es)
|
2012-07-13 |
2018-11-14 |
Ucb Biopharma Sprl |
Derivados de imidazopiridina como moduladores de actividad de TNF
|
|
GB201212513D0
(en)
|
2012-07-13 |
2012-08-29 |
Ucb Pharma Sa |
Therapeutic agents
|
|
JP2015180606A
(ja)
|
2012-08-01 |
2015-10-15 |
アステラス製薬株式会社 |
抗癌剤の併用による癌治療方法
|
|
WO2014020171A1
(fr)
|
2012-08-03 |
2014-02-06 |
Boehringer Ingelheim International Gmbh |
Capacité tampon d'anticorps
|
|
CN104603124B
(zh)
|
2012-08-10 |
2018-04-17 |
勃林格殷格翰国际有限公司 |
用作布鲁顿酪氨酸激酶(btk)抑制剂的杂芳族化合物
|
|
HK1211981A1
(en)
|
2012-09-02 |
2016-06-03 |
Abbvie Inc. |
Methods to control protein heterogeneity
|
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
|
KR102250937B1
(ko)
|
2012-09-11 |
2021-05-12 |
코히러스 바이오사이언시즈, 인코포레이티드 |
고순도 및 탁월한 수율의 정확하게 폴딩된 에타너셉트
|
|
RU2648141C2
(ru)
|
2012-09-19 |
2018-03-22 |
Эббви Биотерапьютикс Инк. |
Способы идентификации антител с пониженной иммуногенностью
|
|
BR122016023101B1
(pt)
|
2012-10-21 |
2022-03-22 |
Pfizer Inc |
Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
|
|
US20150291554A1
(en)
|
2012-11-02 |
2015-10-15 |
Pfizer Inc. |
Bruton's Tyrosine Kinase Inhibitors
|
|
CA2891334C
(fr)
|
2012-11-13 |
2021-10-19 |
Array Biopharma Inc. |
Composes de thio-uree, guanidine, cynoguanidine et d'uree bicycliques utiles pour le traitement de la douleur
|
|
WO2014075697A1
(fr)
|
2012-11-13 |
2014-05-22 |
Biontech Ag |
Agents de traitement de maladies cancéreuses exprimant claudine
|
|
US9844594B2
(en)
|
2012-12-18 |
2017-12-19 |
Merck Sharp & Dohme Corp. |
Liquid formulations for an anti-TNF α antibody
|
|
RU2672053C2
(ru)
|
2012-12-20 |
2018-11-09 |
Пфайзер Инк. |
Способ гликоконъюгации
|
|
US9926341B2
(en)
|
2012-12-20 |
2018-03-27 |
Merck Patent Gmbh |
Copolymers for protein precipitation
|
|
UA111305C2
(uk)
|
2012-12-21 |
2016-04-11 |
Пфайзер Інк. |
Конденсовані лактами арилу та гетероарилу
|
|
CA2896053A1
(fr)
|
2012-12-21 |
2014-06-26 |
Ocata Therapeutics, Inc. |
Procedes de production de plaquettes a partir de cellules souches pluripotentes, et compositions associees
|
|
GB201223276D0
(en)
|
2012-12-21 |
2013-02-06 |
Ucb Pharma Sa |
Antibodies and methods of producing same
|
|
CN105007896B
(zh)
|
2012-12-28 |
2019-04-09 |
雅培心血管系统公司 |
包含抗体的治疗组合物
|
|
EP2752426A1
(fr)
|
2013-01-03 |
2014-07-09 |
Covagen AG |
Composés de liaison d'albumine de sérum humain et leurs protéines de fusion
|
|
GB201300683D0
(en)
|
2013-01-15 |
2013-02-27 |
Apitope Int Nv |
Peptide
|
|
JP2016093104A
(ja)
|
2013-02-19 |
2016-05-26 |
国立大学法人京都大学 |
抗ヒトCD3ε抗体又はそのフラグメント、及びそれを有効成分とする免疫抑制剤
|
|
US10493104B2
(en)
|
2013-02-20 |
2019-12-03 |
Samsung Life Public Welfare Foundation |
Composition for treating inflammatory brain diseases which includes stem cell as active ingredient
|
|
WO2014127785A1
(fr)
|
2013-02-20 |
2014-08-28 |
Ganymed Pharmaceuticals Ag |
Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
|
|
SG11201507230PA
(en)
|
2013-03-12 |
2015-10-29 |
Abbvie Inc |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
|
WO2014151878A2
(fr)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Procédés pour la modulation des profils de glycosylation de protéines de traitements à base de protéines recombinantes au moyen de monosaccharides et d'oligosaccharides
|
|
US9217168B2
(en)
|
2013-03-14 |
2015-12-22 |
Momenta Pharmaceuticals, Inc. |
Methods of cell culture
|
|
EA029052B1
(ru)
|
2013-03-14 |
2018-02-28 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с
|
|
WO2014159579A1
(fr)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
Anticorps anti-tnfα ayant mutés et leurs procédés d'utilisation
|
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
|
CA2906815A1
(fr)
|
2013-03-15 |
2014-09-18 |
Ocata Therapeutics, Inc. |
Photorecepteurs et progeniteurs de photorecepteurs produits a partir de cellules souches pluripotentes
|
|
US9994609B2
(en)
|
2013-03-15 |
2018-06-12 |
Biogen Ma Inc. |
Hydrophobic interaction protein chromatography under no-salt conditions
|
|
PT2970980T
(pt)
|
2013-03-15 |
2018-11-19 |
Janssen Biotech Inc |
Métodos de produção para controlor o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes
|
|
WO2014146672A1
(fr)
|
2013-03-18 |
2014-09-25 |
Ganymed Pharmaceuticals Ag |
Thérapie comprenant des anticorps dirigés contre cldn 18.2 pour le traitement du cancer
|
|
RS57840B1
(sr)
|
2013-03-18 |
2018-12-31 |
Biocerox Prod Bv |
Humanizovana anti-cd 134 (ox40) antitela i njihove upotrebe
|
|
JP2016000003A
(ja)
|
2013-04-19 |
2016-01-07 |
アステラス製薬株式会社 |
新規抗ヒトtweak抗体
|
|
JP6616284B2
(ja)
|
2013-04-23 |
2019-12-04 |
ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ アバディーン |
特異的結合分子の人工ライブラリー
|
|
JP6294872B2
(ja)
|
2013-04-26 |
2018-03-14 |
国立大学法人京都大学 |
脳動脈瘤の形成および/または増大の抑制若しくは縮小用医薬組成物
|
|
WO2014182658A1
(fr)
|
2013-05-06 |
2014-11-13 |
Abbvie Inc. |
Compositions pour culture cellulaire et procédés pour les utiliser
|
|
EP2803668A1
(fr)
|
2013-05-17 |
2014-11-19 |
Boehringer Ingelheim International Gmbh |
Nouveau (cyano-dimethyl-methyl)-isoxazoles et - [1,3,4] thiadiazoles
|
|
HK1214964A1
(zh)
|
2013-05-22 |
2016-08-12 |
Ucb生物制药私人有限公司 |
制备包含治疗性蛋白质的颗粒的方法
|
|
EP3003369A4
(fr)
|
2013-05-28 |
2017-04-26 |
Momenta Pharmaceuticals, Inc. |
Compositions pharmaceutiques comprenant un pyrophosphate
|
|
TWI596107B
(zh)
|
2013-06-25 |
2017-08-21 |
卡地拉保健有限公司 |
單株抗體之新穎純化方法
|
|
NZ715246A
(en)
|
2013-07-06 |
2017-07-28 |
Cadila Healthcare Ltd |
Improved process for production of monoclonal antibodies
|
|
JP6480926B2
(ja)
|
2013-07-23 |
2019-03-13 |
バイオコン・リミテッド |
タンパク質におけるフコシル化レベルを制御するための方法
|
|
CN105745081B
(zh)
|
2013-07-28 |
2019-10-25 |
惠普工业印刷有限公司 |
介质支承装置
|
|
MX371455B
(es)
|
2013-08-02 |
2020-01-28 |
Pfizer |
Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco.
|
|
GB201313888D0
(en)
|
2013-08-02 |
2013-09-18 |
Consort Medical Plc |
Assembly for an autoinjector device
|
|
CU24398B1
(es)
|
2013-08-02 |
2019-04-04 |
Pfizer |
3-(piperidin,pirrol o azetidin)-indoles sustituidos útiles como inhibidores rorc2
|
|
MY177098A
(en)
|
2013-08-09 |
2020-09-05 |
Astellas Pharma Inc |
Novel anti-human tslp receptor antibody
|
|
US20160237399A1
(en)
|
2015-02-18 |
2016-08-18 |
Biogen Ma Inc. |
Control of Protein Glycosylation by Culture Medium Supplementation and Cell Culture Process Parameters
|
|
PL3036320T5
(pl)
|
2013-08-19 |
2024-06-10 |
Biogen Ma Inc. |
Kontrola glikozylacji białka poprzez parametry procesu suplementacji pożywki hodowlanej i hodowli komórkowej
|
|
KR20160065093A
(ko)
|
2013-08-23 |
2016-06-08 |
베링거 인겔하임 에르체파우 게엠베하 운트 코 카게 |
세포 파쇄 및/또는 생체분자 회수를 위한 미세입자
|
|
GB201315487D0
(en)
|
2013-08-30 |
2013-10-16 |
Ucb Pharma Sa |
Antibodies
|
|
JPWO2015041019A1
(ja)
|
2013-09-18 |
2017-03-02 |
国立大学法人京都大学 |
子宮内膜症様細胞の作製方法および子宮内膜症モデル動物
|
|
US10611794B2
(en)
|
2013-09-25 |
2020-04-07 |
Bioverativ Therapeutics Inc. |
On-column viral inactivation methods
|
|
AU2014337263B2
(en)
|
2013-10-16 |
2019-12-12 |
Outlook Therapeutics, Inc. |
Buffer formulations for enhanced antibody stability
|
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
|
GB201320066D0
(en)
|
2013-11-13 |
2013-12-25 |
Ucb Pharma Sa |
Biological products
|
|
CN105814081B
(zh)
|
2013-11-13 |
2021-02-02 |
辉瑞大药厂 |
肿瘤坏死因子样配体1a特异性抗体及其组合物和用途
|
|
US20150139988A1
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
|
GB201321734D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic Agents
|
|
GB201321740D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB201321744D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB201321736D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB201321729D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB201321731D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB201321743D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
ES2809535T3
(es)
|
2013-12-09 |
2021-03-04 |
UCB Biopharma SRL |
Derivados de imidazopiridina como moduladores de la actividad de TNF
|
|
GB201321742D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB201321738D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic Agents
|
|
GB201321749D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB201321735D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic Agents
|
|
GB201321733D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB201321737D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic Agents
|
|
GB201321741D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
US9815797B2
(en)
|
2013-12-09 |
2017-11-14 |
Ucb Biopharma Sprl |
Fused bicyclic heteroaromatic derivatives as modulators of TNF activity
|
|
GB201321746D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB201321745D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB201321739D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB201321748D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB201321730D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB201321728D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB201321732D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
CN104707146B
(zh)
*
|
2013-12-16 |
2019-04-16 |
浙江海正药业股份有限公司 |
一种含有阿达木单抗的药物组合物
|
|
US10273301B2
(en)
|
2013-12-24 |
2019-04-30 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments
|
|
CN109535254B
(zh)
|
2013-12-24 |
2022-06-24 |
安斯泰来制药株式会社 |
抗人bdca-2抗体、其生产方法、多核苷酸、表达载体、宿主细胞及医药组合物
|
|
HUE064292T2
(hu)
|
2013-12-26 |
2024-03-28 |
Mitsubishi Tanabe Pharma Corp |
Humán anti-IL-33 semlegesítõ monoklonális antitest
|
|
FI3583947T3
(fi)
|
2014-01-21 |
2023-10-12 |
Pfizer |
Streptococcus pneumoniaen kapselipolysakkaridit ja niiden konjugaatit
|
|
WO2015110533A2
(fr)
|
2014-01-27 |
2015-07-30 |
Ucb Biopharma Sprl |
Auto-injecteur
|
|
EA032374B1
(ru)
|
2014-01-29 |
2019-05-31 |
ЮСиБи БАЙОФАРМА СПРЛ |
Гетероарильные амиды в качестве ингибиторов агрегации белков
|
|
CA2934965A1
(fr)
|
2014-01-31 |
2016-03-17 |
Boehringer Ingelheim International Gmbh |
Nouveaux anticorps anti-baff
|
|
NZ722391A
(en)
|
2014-02-04 |
2022-12-23 |
Biogen Ma Inc |
Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
|
|
ES2774249T3
(es)
|
2014-02-14 |
2020-07-20 |
Respivert Ltd |
Compuestos heterocíclicos aromáticos como compuestos antiinflamatorios
|
|
USRE47493E1
(en)
|
2014-02-20 |
2019-07-09 |
Boehringer Ingelheim International Gmbh |
Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
|
|
JP6579097B2
(ja)
|
2014-02-28 |
2019-09-25 |
アステラス製薬株式会社 |
新規ヒトtlr2及びヒトtlr4に結合する二重特異的抗体
|
|
US9135573B1
(en)
|
2014-03-17 |
2015-09-15 |
Linkedin Corporation |
Estimating reputation scores in reputation systems
|
|
WO2015141862A1
(fr)
|
2014-03-17 |
2015-09-24 |
Mitsubishi Tanabe Pharma Corporation |
Conjugués anticorps-fynomer
|
|
ES2738416T3
(es)
|
2014-03-19 |
2020-01-22 |
Boehringer Ingelheim Int |
Inhibidores heteroarílicos de SYK
|
|
TW201623277A
(zh)
|
2014-03-26 |
2016-07-01 |
安斯泰來製藥股份有限公司 |
醯胺化合物
|
|
CA2944330A1
(fr)
|
2014-04-02 |
2015-10-08 |
Intas Pharmaceuticals Limited |
Composition pharmaceutique liquide d'adalimumab
|
|
PL3536685T3
(pl)
|
2014-04-04 |
2022-05-16 |
Pfizer Inc. |
Bicykliczne skondensowane związki heteroarylowe lub arylowe i ich zastosowanie jako inhibitory IRAK4
|
|
CN111632167B
(zh)
|
2014-04-15 |
2021-12-28 |
勃林格殷格翰国际公司 |
在制造生物制品期间连续灭活病毒的方法、装置和系统
|
|
BR112016023769A2
(pt)
|
2014-04-17 |
2017-10-17 |
Boehringer Ingelheim Rcv Gmbh |
célula hospedeira recombinante para a expressão de proteínas de interesse
|
|
KR102092225B1
(ko)
|
2014-04-30 |
2020-03-23 |
주식회사 엘지화학 |
고효율 분비능을 가지는 단백질 분비 인자 및 이를 포함하는 발현 벡터
|
|
WO2015173756A2
(fr)
|
2014-05-16 |
2015-11-19 |
Pfizer Inc. |
Anticorps bispécifiques
|
|
PL2946765T3
(pl)
|
2014-05-23 |
2017-08-31 |
Ares Trading S.A. |
Ciekła kompozycja farmaceutyczna
|
|
EP2946766B1
(fr)
|
2014-05-23 |
2016-03-02 |
Ares Trading S.A. |
Composition pharmaceutique liquide
|
|
EP2946767B1
(fr)
|
2014-05-23 |
2016-10-05 |
Ares Trading S.A. |
Composition pharmaceutique liquide
|
|
GB201409558D0
(en)
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
|
ES2864079T3
(es)
|
2014-05-30 |
2021-10-13 |
Pfizer |
Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
|
|
KR20170018810A
(ko)
|
2014-06-10 |
2017-02-20 |
메이지 세이카 파루마 가부시키가이샤 |
안정한 아달리무맙 수성 제제
|
|
AP2016009605A0
(en)
|
2014-06-17 |
2016-12-31 |
Pfizer |
Substituted dihydroisoquinolinone compounds
|
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
|
GB201412658D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
GB201412659D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
EP3172339A1
(fr)
|
2014-07-24 |
2017-05-31 |
Boehringer Ingelheim International GmbH |
Biomarqueurs utiles dans le traitement de maladies associées à l'il-23a
|
|
EA031201B1
(ru)
|
2014-08-06 |
2018-11-30 |
Пфайзер Инк. |
Соединения имидазопиридазина
|
|
PL3178929T3
(pl)
|
2014-08-06 |
2021-12-20 |
Astellas Pharma Inc. |
Nowe przeciwciało przeciwko ludzkiej ig(beta)
|
|
AR101479A1
(es)
|
2014-08-11 |
2016-12-21 |
Boehringer Ingelheim Int |
Derivados de 6-alquinil-piridina
|
|
NO2721710T3
(fr)
|
2014-08-21 |
2018-03-31 |
|
|
|
KR20190062617A
(ko)
|
2014-09-03 |
2019-06-05 |
버베리안 노딕 에이/에스 |
면역 반응을 증대시키기 위한 방법 및 조성물
|
|
US10435464B1
(en)
|
2014-09-05 |
2019-10-08 |
Coherus Biosciences, Inc. |
Methods for making recombinant proteins
|
|
PL3189135T3
(pl)
|
2014-09-05 |
2021-12-20 |
Astellas Institute For Regenerative Medicine |
Komórki zwojowe siatkówki i ich progenitory
|
|
HUE047208T2
(hu)
|
2014-09-12 |
2020-04-28 |
Boehringer Ingelheim Int |
A katepszin-C spirociklikus inhibitorai
|
|
KR20170055540A
(ko)
|
2014-09-17 |
2017-05-19 |
메르크 파텐트 게엠베하 |
뼈 전이 질환 치료 방법, 그에 따른 약제, 및 뼈 전이 질환 치료의 임상 결과 예측 방법
|
|
KR102539788B1
(ko)
|
2014-09-25 |
2023-06-07 |
베링거잉겔하임베트메디카게엠베하 |
말과 동물의 대사 장애를 예방하기 위한 sglt2 억제제와 도파민 작용제의 병용 치료
|
|
MA40759A
(fr)
|
2014-09-26 |
2017-08-01 |
Pfizer |
Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation
|
|
ES2885432T3
(es)
|
2014-10-03 |
2021-12-13 |
Ucb Biopharma Sprl |
Derivados de imidazol pentacíclicos condensados
|
|
HUP1400510A1
(hu)
*
|
2014-10-28 |
2016-05-30 |
Richter Gedeon Nyrt |
Gyógyászati TNFalfa ellenes antitest készítmény
|
|
CN107073022B
(zh)
|
2014-10-31 |
2020-12-29 |
弗雷森纽斯医疗护理德国有限责任公司 |
包含甜菊苷的药物组合物
|
|
KR102265924B1
(ko)
|
2014-10-31 |
2021-06-15 |
삼성바이오에피스 주식회사 |
Pdk 불활성화에 의한 폴리펩타이드의 생산
|
|
MX370366B
(es)
|
2014-11-14 |
2019-12-11 |
Boehringer Ingelheim Int |
Amidas de morfolina y 1,4-oxazepano como agonistas del receptor de somatostatina subtipo 4 (sstr4).
|
|
EP3241844B1
(fr)
|
2014-12-03 |
2021-04-21 |
Aimed Bio Inc. |
Anticorps dirigé contre la neuropiline 1 et son utilisation
|
|
KR20160068558A
(ko)
|
2014-12-05 |
2016-06-15 |
삼성바이오에피스 주식회사 |
마우스 cmv 프로모터를 포함하는 융합 폴리뉴클레오타이드 및 이를 이용한 목적 폴리펩타이드의 생산 방법
|
|
JP6807327B2
(ja)
|
2014-12-22 |
2021-01-06 |
ユーシービー バイオファルマ エスアールエル |
タンパク質製造
|
|
CA2970577A1
(fr)
|
2014-12-22 |
2016-06-30 |
Ares Trading S.A. |
Composition pharmaceutique liquide
|
|
ES3046837T3
(en)
|
2014-12-22 |
2025-12-02 |
UCB Biopharma SRL |
Method of protein manufacture
|
|
US20170360929A1
(en)
*
|
2014-12-23 |
2017-12-21 |
Pfizer Inc. |
Stable aqueous antibody formulation for anti tnf alpha antibodies
|
|
EP3247718B1
(fr)
|
2015-01-21 |
2021-09-01 |
Outlook Therapeutics, Inc. |
Modulation de variants de charge dans une composition d'anticorps monoclonaux
|
|
EP3250598A1
(fr)
*
|
2015-01-28 |
2017-12-06 |
Mabxience S.A. |
Formulations pharmaceutiques pour des anticorps anti-tnf-alpha
|
|
WO2016120850A1
(fr)
|
2015-01-30 |
2016-08-04 |
Pfizer Inc. |
Modulateurs indole de rorc2 substitués par sulfonamide et leurs procédés d'utilisation
|
|
GB201501613D0
(en)
|
2015-01-30 |
2015-03-18 |
Ucb Biopharma Sprl |
Treatment of autoimmune disorders with CD154 antibodies
|
|
JP2018505878A
(ja)
|
2015-01-30 |
2018-03-01 |
ファイザー・インク |
Rorc2のメトキシ置換ピロロピリジンモジュレーターならびにその使用方法
|
|
EP3053572A1
(fr)
|
2015-02-06 |
2016-08-10 |
Ares Trading S.A. |
Composition pharmaceutique liquide
|
|
US20180008707A1
(en)
*
|
2015-02-13 |
2018-01-11 |
Sanofi |
Stable liquid formulation for monoclonal antibodies
|
|
US20180079796A1
(en)
|
2015-03-13 |
2018-03-22 |
Samsung Bioepis Co., Ltd. |
Anti-tnf-alpha polypeptide composition and use thereof
|
|
US11505784B2
(en)
|
2015-04-01 |
2022-11-22 |
Boehringer Ingelheim International Gmbh |
Cell culture medium
|
|
WO2016162819A1
(fr)
*
|
2015-04-07 |
2016-10-13 |
Lupin Limited |
Composition pharmaceutique aqueuse stable d'anticorps anti-tnf alpha
|
|
EP3078675A1
(fr)
|
2015-04-10 |
2016-10-12 |
Ares Trading S.A. |
Régime de dosage à induction pour le traitement des maladies liées au tnf alpha
|
|
TWI700298B
(zh)
|
2015-04-13 |
2020-08-01 |
美商輝瑞股份有限公司 |
靶向b細胞成熟抗原之嵌合型抗原受體類
|
|
MX2017013156A
(es)
|
2015-04-14 |
2018-02-21 |
Boehringer Ingelheim Int |
Metodos para tratar enfermedades.
|
|
WO2016165765A1
(fr)
|
2015-04-15 |
2016-10-20 |
Ganymed Pharmaceuticals Ag |
Procédés et compositions permettant de prédire l'efficacité thérapeutique des traitements contre le cancer et de pronostiquer un cancer
|
|
EP3081227A1
(fr)
|
2015-04-15 |
2016-10-19 |
Institut National De La Recherche Agronomique |
Lactococcus lactis produisant du tslp ou il-25 et leurs utilisations comme probiotiques et thérapeutiques
|
|
GB201506786D0
(en)
|
2015-04-21 |
2015-06-03 |
Ucb Biopharma Sprl |
Therapeutic use
|
|
CA2983898A1
(fr)
|
2015-04-28 |
2016-11-03 |
Mitsubishi Tanabe Pharma Corporation |
Proteine de liaison a rgma et son utilisation
|
|
EP3290037A4
(fr)
|
2015-04-28 |
2019-01-23 |
Astellas Pharma Inc. |
Composition pharmaceutique pour administration par voie orale
|
|
KR20170138570A
(ko)
|
2015-04-30 |
2017-12-15 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
대사 장애를 치료하기 위한 항-aP2 항체 및 항원 결합 물질
|
|
KR102143534B1
(ko)
|
2015-05-04 |
2020-08-12 |
화이자 인코포레이티드 |
B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
|
|
JP6851322B2
(ja)
|
2015-05-27 |
2021-03-31 |
ユーシービー バイオファルマ エスアールエル |
神経疾患を治療する方法
|
|
US20180291329A1
(en)
|
2015-05-29 |
2018-10-11 |
Biogen Ma Inc. |
Cell culture methods and systems
|
|
WO2016193844A1
(fr)
|
2015-05-29 |
2016-12-08 |
Pfizer Inc. |
Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de l'enzyme vanine-1
|
|
GB201509888D0
(en)
|
2015-06-08 |
2015-07-22 |
Ucb Biopharma Sprl |
Therapeutic agents
|
|
GB201509885D0
(en)
|
2015-06-08 |
2015-07-22 |
Ucb Biopharma Sprl |
Therapeutic agents
|
|
GB201509893D0
(en)
|
2015-06-08 |
2015-07-22 |
Ucb Biopharma Sprl |
Therapeutic agents
|
|
DK3310784T3
(da)
|
2015-06-17 |
2020-11-09 |
Pfizer |
Tricykliske forbindelser og deres anvendelse som phosphodiesterasehæmmere
|
|
GB201510758D0
(en)
|
2015-06-18 |
2015-08-05 |
Ucb Biopharma Sprl |
Novel TNFa structure for use in therapy
|
|
AR105025A1
(es)
|
2015-06-19 |
2017-08-30 |
Astellas Pharma Inc |
Compuesto de imidazodiazepina
|
|
US20170044265A1
(en)
|
2015-06-24 |
2017-02-16 |
Janssen Biotech, Inc. |
Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
|
|
EA034885B1
(ru)
|
2015-07-03 |
2020-04-02 |
Астеллас Фарма Юэроп Лтд. |
Новая схема лечения тиакумициновым соединением
|
|
SG10202010735PA
(en)
|
2015-07-06 |
2020-11-27 |
UCB Biopharma SRL |
Tau-binding antibodies
|
|
CA2991264C
(fr)
|
2015-07-06 |
2023-10-10 |
Ucb Biopharma Sprl |
Anticorps se liant a tau
|
|
KR20250058066A
(ko)
|
2015-07-21 |
2025-04-29 |
화이자 인코포레이티드 |
접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
|
|
PE20180774A1
(es)
|
2015-07-23 |
2018-05-07 |
Boehringer Ingelheim Int |
Compuesto que se dirige a il-23a y al factor de activacion de linfocitos b (baff) y usos de estos
|
|
PT3333165T
(pt)
|
2015-08-04 |
2019-10-29 |
Astellas Pharma Inc |
Derivado de piperazina
|
|
KR102411018B1
(ko)
|
2015-08-18 |
2022-06-20 |
아스텔라스 인스티튜트 포 리제너러티브 메디슨 |
임상 제제
|
|
HRP20210472T1
(hr)
|
2015-08-27 |
2021-05-14 |
Pfizer Inc. |
Biciklički kondenzirani heteroarilni ili arilni spojevi kao modulatori irak4
|
|
BR112018001907A2
(pt)
|
2015-09-01 |
2018-09-25 |
Boehringer Ingelheim Int |
uso de anticorpos anti-cd40 para o tratamento de nefrite lúpica
|
|
AR106026A1
(es)
|
2015-09-29 |
2017-12-06 |
Merial Inc |
Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos
|
|
PE20181367A1
(es)
|
2015-09-30 |
2018-08-27 |
Janssen Biotech Inc |
Anticuerpos agonistas que se unen especificamente a cd40 humana y metodos de uso
|
|
EP3359688B1
(fr)
|
2015-10-05 |
2021-06-16 |
UCB Biopharma SRL |
Signatures moléculaires pour une utilisation dans le diagnostic et l'analyse de la réponse au traitement de maladies auto-immunes
|
|
KR101949451B1
(ko)
|
2015-10-13 |
2019-05-10 |
주식회사 이노파마스크린 |
염증성 장 질환 및 아토피 피부염 치료용 조성물
|
|
EP3365335B1
(fr)
|
2015-10-23 |
2024-02-14 |
Array Biopharma, Inc. |
Composés de 2-pyridazin-3(2h)-one à substitution 2-aryle et 2-hétéroaryle utilisés en tant qu'inhibiteurs de fgfr tyrosine kinases
|
|
CN108350068A
(zh)
|
2015-10-27 |
2018-07-31 |
Ucb生物制药私人有限公司 |
使用抗-il-17a/f抗体的治疗方法
|
|
BR112018008908A2
(pt)
|
2015-11-02 |
2018-11-27 |
Janssen Pharmaceutica Nv |
anticorpos anti-il1rap, moléculas de ligação ao antígeno biespecíficas que se ligam il1rap e cd3, e seus usos
|
|
HRP20211518T1
(hr)
|
2015-11-03 |
2021-12-24 |
UCB Biopharma SRL |
Postupak priprave brivaracetama
|
|
JP6797206B2
(ja)
|
2015-11-23 |
2020-12-09 |
ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド |
Fmdv及びe2融合タンパク質並びにその使用
|
|
TWI812873B
(zh)
|
2015-11-30 |
2023-08-21 |
美商輝瑞股份有限公司 |
用於部位專一性接合之抗體和抗體片段
|
|
GB201521383D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl And Ucb Celltech |
Method
|
|
GB201521391D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521393D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521382D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521389D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Method
|
|
HRP20211845T1
(hr)
|
2015-12-16 |
2022-03-04 |
Boehringer Ingelheim International Gmbh |
Derivati bipirazolila korisni za liječenje autoimunih bolesti
|
|
US10994011B2
(en)
|
2015-12-18 |
2021-05-04 |
Astellas Pharma Inc. |
Pharmaceutical composition comprising anti-human TSLP receptor antibody
|
|
GB201522391D0
(en)
|
2015-12-18 |
2016-02-03 |
Ucb Biopharma Sprl |
Antibody molecules
|
|
US10570118B2
(en)
|
2016-01-13 |
2020-02-25 |
Boehringer Ingelheim International Gmbh |
Isoquinolones as BTK inhibitors
|
|
CA2954892A1
(fr)
|
2016-01-19 |
2017-07-19 |
Pfizer Inc. |
Immunogenes derives d'antigenes associes a une tumeur ou des modules d'acide nucleique codant les immunogenes
|
|
FI3405177T3
(fi)
|
2016-01-19 |
2026-06-03 |
Janssen Pharmaceutica Nv |
Btk:n estäjää käsittäviä formulaatioita/koostumuksia
|
|
DK3405178T3
(da)
|
2016-01-19 |
2025-09-22 |
Janssen Pharmaceutica Nv |
Formuleringer/sammensætninger, der omfatter en btk-inhibitor
|
|
ES2904593T3
(es)
|
2016-01-21 |
2022-04-05 |
Pfizer |
Anticuerpos monoespecíficos y biespecíficos para la variante III del receptor del factor de crecimiento epidérmico y CD3 y sus usos
|
|
BR112018014585A2
(pt)
|
2016-01-21 |
2018-12-11 |
Pfizer |
receptores de antígeno quiméricos que direcionam o receptor do fator de crescimento epidérmico variante iii
|
|
WO2017132457A1
(fr)
|
2016-01-28 |
2017-08-03 |
Janssen Biotech, Inc. |
Anticorps bispécifiques anti-tnf-α/il-17a antibodies et anticorps anti-tnf-α et leurs procédés d'utilisation
|
|
TWI760322B
(zh)
|
2016-01-29 |
2022-04-11 |
美商百靈佳殷格翰動物保健美國有限公司 |
重組腺病毒載體裝載之fmdv疫苗及其用途
|
|
US10465003B2
(en)
|
2016-02-05 |
2019-11-05 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
|
|
US11590239B2
(en)
|
2016-02-08 |
2023-02-28 |
Synaffix B.V. |
Antibody-conjugates with improved therapeutic index for targeting CD30 tumours and method for improving therapeutic index of antibody-conjugates
|
|
DE102016001407A1
(de)
|
2016-02-09 |
2017-08-24 |
Fresenius Medical Care Deutschland Gmbh |
Blutbehandlung mit Inaktivierung von freien Nukleinsäuren
|
|
GB201602938D0
(en)
|
2016-02-19 |
2016-04-06 |
Ucb Biopharma Sprl |
Protein purification
|
|
KR102148587B1
(ko)
|
2016-02-23 |
2020-08-26 |
화이자 인코포레이티드 |
6,7-디히드로-5H-피라졸로[5,1-b][1,3]옥사진-2-카르복스아미드 화합물
|
|
GB201603104D0
(en)
|
2016-02-23 |
2016-04-06 |
Ucb Biopharma Sprl |
Therapeutic agents
|
|
MX383747B
(es)
|
2016-02-24 |
2025-03-14 |
Pfizer |
Derivados de pirazolo[1,5-a]pirazin-4-ilo como inhibidores de quinasas janus (jak)
|
|
KR102550844B1
(ko)
|
2016-03-11 |
2023-07-05 |
베링거 인겔하임 인터내셔날 게엠베하 |
단백질의 제조 동안 바이러스를 연속적으로 불활성화시키는 방법
|
|
US10611800B2
(en)
|
2016-03-11 |
2020-04-07 |
Pfizer Inc. |
Human cytomegalovirus gB polypeptide
|
|
US10519479B1
(en)
|
2016-03-15 |
2019-12-31 |
Ares Trading S.A. |
Methods for modifying glycosylation using manganese
|
|
US10526631B1
(en)
|
2016-03-15 |
2020-01-07 |
Ares Trading S.A. |
Method of reducing serine for asparagine misincorporation
|
|
ES2947570T3
(es)
|
2016-03-15 |
2023-08-11 |
Astellas Pharma Inc |
Comprimido
|
|
KR102023058B1
(ko)
|
2016-03-25 |
2019-09-19 |
사회복지법인 삼성생명공익재단 |
이중 이온 pH-민감성 공중합체를 이용한 허혈성 뇌질환 치료용 약물 전달체
|
|
EP3436014A4
(fr)
|
2016-03-29 |
2019-11-27 |
Astellas Pharma Inc. |
Polythérapie pour le traitement de la leucémie myéloïde aiguë
|
|
WO2017167993A1
(fr)
|
2016-04-01 |
2017-10-05 |
Ucb Biopharma Sprl |
Dérivés d'imidazole pentacycliques condensés utilisés en tant que modulateurs de l'activité du tnf
|
|
CN108883345B
(zh)
|
2016-04-01 |
2022-09-13 |
Ucb生物制药私人有限公司 |
用于蛋白纯化的方法
|
|
CN109219609B
(zh)
|
2016-04-01 |
2022-02-01 |
Ucb生物制药私人有限公司 |
作为tnf活性调节剂的稠合六环咪唑衍生物
|
|
CA3019245A1
(fr)
|
2016-04-01 |
2017-10-05 |
Ucb Biopharma Sprl |
Derives d'imidazole pentacycliques condenses utilises en tant que modulateurs de l'activite du tnf
|
|
WO2017167996A1
(fr)
|
2016-04-01 |
2017-10-05 |
Ucb Biopharma Sprl |
Dérivés d'imidazole pentacycliques condensés utilisés en tant que modulateurs de l'activité du tnf
|
|
JPWO2017175792A1
(ja)
|
2016-04-06 |
2019-02-14 |
アステラス製薬株式会社 |
速溶出性三次元造形物、速溶出性三次元造形物用フィラメント及び速溶出性三次元造形物用材料
|
|
US10485857B2
(en)
|
2016-04-07 |
2019-11-26 |
Boehringer Ingelheim Animal Health USA Inc. |
Heartworm vaccine, methods and uses thereof
|
|
CN108884050B
(zh)
|
2016-04-13 |
2022-07-05 |
Ucb生物制药私人有限公司 |
四氢异喹啉衍生物
|
|
JP7250520B2
(ja)
|
2016-04-13 |
2023-04-03 |
ヤンセン ファーマシューティカルズ,インコーポレーテッド |
組換えアルテリウイルスレプリコン系およびその使用
|
|
WO2017178586A1
(fr)
|
2016-04-15 |
2017-10-19 |
Cellectis |
Méthode de mise au point par génie génétique de lymphocytes t hypersensibles à un promédicament spécifique pour une immunothérapie par expression génique
|
|
PE20190115A1
(es)
|
2016-04-15 |
2019-01-16 |
Immunext Inc |
Anticuerpos vista antihumanos y su uso
|
|
KR20170122650A
(ko)
|
2016-04-27 |
2017-11-06 |
사회복지법인 삼성생명공익재단 |
미숙아 뇌실내 출혈 치료를 위한 고효능 줄기세포 선별법
|
|
SG11201808693WA
(en)
|
2016-04-27 |
2018-11-29 |
Pfizer |
Anti-il-33 antibodies, compositions, methods and uses thereof
|
|
CN109071643B
(zh)
|
2016-05-01 |
2024-03-19 |
Ucb生物制药有限责任公司 |
亲和力改造的血清蛋白载体结合结构域
|
|
WO2017194605A1
(fr)
|
2016-05-10 |
2017-11-16 |
Ares Trading S.A. |
Procédés de modulation de profils de galactosylation de protéines de protéines recombinantes à l'aide de galactose peracétyle
|
|
GB201608323D0
(en)
|
2016-05-12 |
2016-06-29 |
Ucb Biopharma Sprl |
Pharmaceutical compositions
|
|
GB201608797D0
(en)
|
2016-05-19 |
2016-07-06 |
Ucb Biopharma Sprl |
Therapeutic use
|
|
US20190336552A1
(en)
|
2016-05-30 |
2019-11-07 |
Astellas Pharma Inc. |
Genetically engineered vaccinia viruses
|
|
GB201610044D0
(en)
|
2016-06-08 |
2016-07-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
TW201808987A
(zh)
|
2016-06-08 |
2018-03-16 |
健生生物科技公司 |
Gm-csf變體及使用方法
|
|
GB201610198D0
(en)
|
2016-06-10 |
2016-07-27 |
Ucb Biopharma Sprl |
Anti-ige antibodies
|
|
US10906888B2
(en)
|
2016-07-14 |
2021-02-02 |
Pfizer Inc. |
Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme
|
|
US10925956B2
(en)
|
2016-07-15 |
2021-02-23 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against a marburg virus infection
|
|
US10710988B2
(en)
|
2016-07-19 |
2020-07-14 |
Astellas Pharma Inc. |
Piperazine derivative
|
|
WO2018022851A1
(fr)
|
2016-07-28 |
2018-02-01 |
Mitobridge, Inc. |
Méthode de traitement de lésions rénales aiguës.
|
|
MX2019001153A
(es)
|
2016-07-29 |
2019-06-10 |
Pfizer |
Peptidos ciclicos como antagonistas del receptor c5a.
|
|
US11053553B2
(en)
|
2016-08-10 |
2021-07-06 |
Astellas Pharma Inc. |
Detection of CLDN18-ARHGAP6 fusion gene or CLDN18-ARHGAP26 fusion gene in pancreatic cancer
|
|
CA3031860A1
(fr)
|
2016-08-17 |
2018-02-22 |
Boehringer Ingelheim International Gmbh |
Procede de preparation de formulations liquides hautement concentrees contenant des biomolecules
|
|
WO2018035330A1
(fr)
|
2016-08-19 |
2018-02-22 |
Janssen Biotech, Inc. |
Méthodes de traitement de la maladie de crohn avec un anticorps anti-nkg2d
|
|
JP7051820B2
(ja)
|
2016-09-12 |
2022-04-11 |
アレス トレーディング ソシエテ アノニム |
組換えタンパク質の生産プロファイルを改変するための方法
|
|
US10138241B2
(en)
|
2016-09-15 |
2018-11-27 |
Boehringer Ingelheim International Gmbh |
Substituted benzamides as RIPK2 inhibitors
|
|
BR112019005328A2
(pt)
|
2016-09-27 |
2019-06-18 |
Fresenius Kabi Deutschland Gmbh |
composição farmacêutica líquida
|
|
GB201616563D0
(en)
|
2016-09-29 |
2016-11-16 |
Ucb Biopharma Sprl |
Therapeutic agents
|
|
US10537590B2
(en)
|
2016-09-30 |
2020-01-21 |
Boehringer Ingelheim International Gmbh |
Cyclic dinucleotide compounds
|
|
KR101971322B1
(ko)
|
2016-10-17 |
2019-04-23 |
사회복지법인 삼성생명공익재단 |
Socs의 발현 또는 활성 억제를 이용한 고효능 줄기세포 선별방법
|
|
IL310865A
(en)
|
2016-10-17 |
2024-04-01 |
Pfizer |
Antibodies against EDB and antibody-drug conjugates
|
|
KR101971323B1
(ko)
|
2016-10-17 |
2019-04-23 |
사회복지법인 삼성생명공익재단 |
면역질환 치료를 위한 고효능 줄기세포 선별방법
|
|
GB201617924D0
(en)
|
2016-10-24 |
2016-12-07 |
Ucb Biopharma Sprl |
Proteins and users
|
|
JPWO2018079570A1
(ja)
|
2016-10-26 |
2019-09-19 |
アステラス製薬株式会社 |
安定な医薬組成物
|
|
KR101837449B1
(ko)
|
2016-10-28 |
2018-03-12 |
삼성전자주식회사 |
마이크로 니들 패치, 마이크로 니들을 제조하는 방법 및 장치
|
|
BR112019006853B1
(pt)
|
2016-10-31 |
2021-08-24 |
Fresenius Kabi Deutschland Gmbh |
Composição farmacêutica líquida, seu método de fabricação, seu uso, kit e dispositivo de liberação de fármaco que a compreendem e método de fabricação do dito dispositivo
|
|
EP3532500A1
(fr)
|
2016-10-31 |
2019-09-04 |
Vectura Limited |
Composition de poudre inhalable comprenant un anticorps il -13
|
|
WO2018092885A1
(fr)
|
2016-11-18 |
2018-05-24 |
アステラス製薬株式会社 |
NOUVEAU FRAGMENT Fab D'ANTICORPS ANTI-MUC1 HUMAIN
|
|
WO2018098213A1
(fr)
|
2016-11-23 |
2018-05-31 |
Wake Forest University Health Sciences |
Analyse d'image médicale à l'aide d'informations de déformation mécanique
|
|
GB201620948D0
(en)
|
2016-12-09 |
2017-01-25 |
Ucb Biopharma Sprl |
Therapeutic agents
|
|
CA3046432A1
(fr)
|
2016-12-13 |
2018-06-21 |
Astellas Pharma Inc. |
Anticorps anti-cd73 humain
|
|
GB201621728D0
(en)
|
2016-12-20 |
2017-02-01 |
Ucb Biopharma Sprl |
Methods
|
|
EP3824906A1
(fr)
|
2016-12-21 |
2021-05-26 |
Amgen Inc. |
Formulations d'anticorps anti-tnf alpha
|
|
TWI754702B
(zh)
|
2016-12-28 |
2022-02-11 |
德商Ucb製藥有限公司 |
(氮雜)吲哚-和苯並呋喃-3-磺醯胺類
|
|
BR112019014833A2
(pt)
|
2017-01-20 |
2020-04-14 |
Pfizer |
composições imunogênicas para uso em vacinas pneumococais
|
|
EP3573995A1
(fr)
|
2017-01-24 |
2019-12-04 |
Pfizer Inc. |
Dérivés de calichéamicine et conjugués anticorps-médicaments de ceux-ci
|
|
TWI764976B
(zh)
|
2017-01-24 |
2022-05-21 |
日商安斯泰來製藥股份有限公司 |
取代苯基二氟甲基之脯胺酸醯胺化合物
|
|
RU2019126170A
(ru)
|
2017-01-26 |
2021-02-26 |
Юсб Байофарма Спрл |
Бисгетероарильные производные в качестве модуляторов агрегации белков
|
|
US10889584B2
(en)
|
2017-01-26 |
2021-01-12 |
UCB Biopharma SRL |
Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation
|
|
CN110234351A
(zh)
|
2017-01-30 |
2019-09-13 |
詹森生物科技公司 |
用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
|
|
JOP20190186A1
(ar)
|
2017-02-02 |
2019-08-01 |
Astellas Pharma Inc |
مركب كينازولين
|
|
KR20240038148A
(ko)
|
2017-02-07 |
2024-03-22 |
얀센 바이오테크 인코포레이티드 |
활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
|
|
JP7145162B2
(ja)
|
2017-02-16 |
2022-09-30 |
ヤンセン バイオテク,インコーポレイテッド |
化膿性汗腺炎の処置
|
|
CN119242587A
(zh)
|
2017-02-17 |
2025-01-03 |
隆萨有限公司 |
难以表达的蛋白质的多位点特异性整合细胞
|
|
MA47676A
(fr)
|
2017-03-01 |
2021-06-02 |
Janssen Sciences Ireland Unlimited Co |
Polythérapie
|
|
EP3372242A1
(fr)
|
2017-03-06 |
2018-09-12 |
Ares Trading S.A. |
Composition pharmaceutique liquide
|
|
EP3372241A1
(fr)
|
2017-03-06 |
2018-09-12 |
Ares Trading S.A. |
Composition pharmaceutique liquide
|
|
ES2910083T3
(es)
|
2017-03-10 |
2022-05-11 |
Pfizer |
Derivados de imidazo[4,5-c]quinolina cíclicos sustituidos
|
|
WO2018167176A1
(fr)
|
2017-03-15 |
2018-09-20 |
Ucb Biopharma Sprl |
Dérivés d'imidazole pentacycliques condensés utilisés en tant que modulateurs de l'activité du tnf
|
|
JP6901292B2
(ja)
|
2017-03-15 |
2021-07-14 |
株式会社Adeka |
水溶性組成物、その硬化物の製造方法、およびその硬化物、並びにアシルホスフィン酸塩
|
|
CA3050614A1
(fr)
|
2017-03-17 |
2018-09-20 |
Curevac Ag |
Vaccin a arn et inhibiteurs de points de controle immunitaires pour une therapie anticancereuse combinee
|
|
JOP20190218A1
(ar)
|
2017-03-22 |
2019-09-22 |
Boehringer Ingelheim Int |
مركبات ثنائية النيوكليوتيدات حلقية معدلة
|
|
CN110475567A
(zh)
|
2017-03-31 |
2019-11-19 |
勃林格殷格翰国际有限公司 |
抗癌组合疗法
|
|
PH12019502182B1
(en)
|
2017-04-25 |
2024-01-31 |
Sanofi Sa |
Fused pentacyclic imidazole derivatives as modulators of tnf activity
|
|
EP3615687A4
(fr)
|
2017-04-26 |
2021-01-13 |
The RNA Medicines Company, Inc. |
Agents de liaison d'oligonucléotides
|
|
KR20200014379A
(ko)
|
2017-06-05 |
2020-02-10 |
얀센 바이오테크 인코포레이티드 |
비대칭 ch2-ch3 영역 돌연변이를 갖는 조작된 다중특이성 항체 및 다른 다량체 단백질
|
|
AU2018285131B2
(en)
|
2017-06-12 |
2021-11-11 |
Boehringer Ingelheim International Gmbh |
Heteroaromatic compounds as Vanin inhibitors
|
|
GB201709456D0
(en)
|
2017-06-14 |
2017-07-26 |
Ucb Biopharma Sprl |
Therapeutic agents
|
|
KR102787394B1
(ko)
|
2017-07-14 |
2025-03-26 |
화이자 인크. |
MAdCAM에 대한 항체
|
|
WO2019018647A1
(fr)
|
2017-07-20 |
2019-01-24 |
Pfizer Inc. |
Anticorps anti-gd3 et conjugués anticorps-médicament
|
|
KR102531749B1
(ko)
|
2017-08-11 |
2023-05-10 |
베링거 인겔하임 인터내셔날 게엠베하 |
Cho 세포 내 통합 부위
|
|
WO2019034973A1
(fr)
|
2017-08-14 |
2019-02-21 |
Pfizer Inc. |
Pyrazolo[1,5-a]pyrazin-4-yl et dérivés associés
|
|
WO2019035649A1
(fr)
|
2017-08-14 |
2019-02-21 |
주식회사 레고켐 바이오사이언스 |
Conjugués anticorps-médicament comprenant un anticorps contre egfrviii
|
|
WO2019038338A1
(fr)
|
2017-08-23 |
2019-02-28 |
Sandoz Ag |
Système d'expression de protéines à multiples copies géniques
|
|
CA3074317C
(fr)
|
2017-08-25 |
2024-06-18 |
Janssen Biotech, Inc. |
Domaines de type iii de fibronectine liant fc.gamma.rii, leurs conjugues et molecules multispecifiques les comprenant
|
|
EP3676281A1
(fr)
|
2017-08-30 |
2020-07-08 |
Ares Trading S.A. |
Procédé de purification de protéines
|
|
WO2019045075A1
(fr)
|
2017-08-31 |
2019-03-07 |
田辺三菱製薬株式会社 |
Agent thérapeutique contenant un antagoniste de l'il-33 pour traiter l'endométriose
|
|
US11573224B2
(en)
|
2017-09-14 |
2023-02-07 |
Icagen, Llc |
Methods of detection using X-ray fluorescence
|
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗il12/il23抗體治療狼瘡之安全且有效之方法
|
|
WO2019059741A1
(fr)
|
2017-09-25 |
2019-03-28 |
사회복지법인 삼성생명공익재단 |
Forme posologique à base de cellules souches contenant du liquide céphalo-rachidien et son procédé de production
|
|
US11364303B2
(en)
|
2017-09-29 |
2022-06-21 |
Pfizer Inc. |
Cysteine engineered antibody drug conjugates
|
|
WO2019066435A2
(fr)
|
2017-09-29 |
2019-04-04 |
재단법인 목암생명과학연구소 |
Anticorps anti-bcma ayant une affinité élevée pour bcma et composition pharmaceutique pour le traitement du cancer, comprenant celui-ci
|
|
US20190100587A1
(en)
|
2017-10-02 |
2019-04-04 |
Covagen Ag |
IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
|
|
US20190153096A1
(en)
|
2017-10-02 |
2019-05-23 |
Covagen Ag |
Cd3/cd33 bispecific binding molecules
|
|
US11707522B2
(en)
|
2017-10-13 |
2023-07-25 |
Boehringer Ingelheim International Gmbh |
Human antibodies to Tn antigen
|
|
JP7117374B2
(ja)
|
2017-10-13 |
2022-08-12 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
灌流培地
|
|
AU2018347331A1
(en)
|
2017-10-13 |
2020-04-09 |
Merck Patent Gmbh |
Combination of a PARP inhibitor and a PD-1 axis binding antagonist
|
|
KR20200072507A
(ko)
|
2017-10-19 |
2020-06-22 |
데비오팜 인터네셔날 에스 에이 |
암 치료를 위한 조합 제품
|
|
WO2019082020A1
(fr)
|
2017-10-27 |
2019-05-02 |
Pfizer Inc. |
Anticorps et conjugués anticorps-médicament spécifiques à cd123 et leurs utilisations
|
|
MX2020004716A
(es)
|
2017-11-06 |
2020-11-06 |
Janssen Biotech Inc |
Método seguro y eficaz para tratar la artritis psoriásica con el anticuerpo específico anti-il23.
|
|
WO2019099970A1
(fr)
|
2017-11-20 |
2019-05-23 |
Janssen Pharmaceuticals Inc. |
Procédé d'administration sûre de vecteurs adénoviraux codant pour un antigène du virus zika
|
|
GB201719447D0
(en)
|
2017-11-23 |
2018-01-10 |
Ucb Biopharma Sprl |
Pharmaceutical composition
|
|
KR20190064293A
(ko)
|
2017-11-30 |
2019-06-10 |
(주)메디노 |
미숙아 뇌실내 출혈 치료를 위한 고효능 줄기세포 선별법
|
|
CN111615520A
(zh)
|
2017-12-01 |
2020-09-01 |
辉瑞大药厂 |
抗cxcr5抗体及其组合物和用途
|
|
GB201720970D0
(en)
|
2017-12-15 |
2018-01-31 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201720975D0
(en)
|
2017-12-15 |
2018-01-31 |
Ucb Biopharma Sprl |
Anti-alpha synuclein antibodies
|
|
TW201938165A
(zh)
|
2017-12-18 |
2019-10-01 |
美商輝瑞股份有限公司 |
治療癌症的方法及組合療法
|
|
EA202091516A1
(ru)
|
2017-12-19 |
2020-11-03 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
|
|
JP2021506300A
(ja)
|
2017-12-19 |
2021-02-22 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
B型肝炎ウイルス(hbv)に対する免疫応答を誘導するための方法および組成物
|
|
JP7267284B2
(ja)
|
2017-12-20 |
2023-05-01 |
アレス トレーディング ソシエテ アノニム |
ポリエーテルイオノフォアを使用するタンパク質マンノシル化プロファイルの調節方法
|
|
EP3727374A4
(fr)
|
2017-12-21 |
2021-11-10 |
Merck Patent GmbH |
Association d'un anticorps anti-pd-l1 et d'un inhibiteur de l'ido1 pour le traitement du cancer
|
|
CN111601799B
(zh)
|
2018-01-15 |
2023-06-09 |
Ucb生物制药有限责任公司 |
作为Il-17调节剂的稠合咪唑衍生物
|
|
AU2019206724A1
(en)
|
2018-01-15 |
2020-07-16 |
Kite Pharma, Inc. |
Methods of administering chimeric antigen receptor immunotherapy in combination with 4-1BB agonist
|
|
MX2020008183A
(es)
|
2018-02-01 |
2020-09-22 |
Pfizer |
Anticuerpos especificos para cd70 y sus usos.
|
|
MX2020008184A
(es)
|
2018-02-01 |
2020-09-22 |
Pfizer |
Receptores de antigeno quimericos dirigidos a cd70.
|
|
TW202430218A
(zh)
|
2018-02-27 |
2024-08-01 |
美商輝瑞大藥廠 |
抗體純化
|
|
MX387358B
(es)
|
2018-02-28 |
2025-03-18 |
Pfizer |
Variantes de il-15 y usos de las mismas
|
|
AU2019227979B2
(en)
|
2018-03-02 |
2024-09-05 |
Allogene Therapeutics, Inc. |
Inducible chimeric cytokine receptors
|
|
JP7516250B2
(ja)
|
2018-03-05 |
2024-07-16 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il-23特異的抗体を用いたクローン病の治療方法
|
|
IL277095B2
(en)
|
2018-03-07 |
2025-10-01 |
Pfizer |
Preparations containing anti-PD-1 antibody
|
|
WO2019177883A2
(fr)
|
2018-03-14 |
2019-09-19 |
Boehringer Ingelheim International Gmbh |
Utilisation d'anticorps anti-il-36 r pour le traitement d'une maladie intestinale inflammatoire
|
|
AU2019236105B2
(en)
|
2018-03-14 |
2025-07-31 |
Boehringer Ingelheim International Gmbh |
Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
|
|
US20210024567A1
(en)
|
2018-03-27 |
2021-01-28 |
Boehringer Ingelheim International Gmbh |
Modified cyclic dinucleotide compounds
|
|
WO2019185477A1
(fr)
|
2018-03-27 |
2019-10-03 |
Boehringer Ingelheim International Gmbh |
Composés dinucléotidiques cycliques contenant 2-aza-hypoxanthine ou 6h-pytazolo[1,5-d][1,2,4]triazine-7-one en tant qu'agonistes de sting
|
|
SI3781943T1
(sl)
|
2018-04-20 |
2022-07-29 |
Janssen Biotech, Inc. |
Kvalifikacija kromatografske kolone v proizvodnih postopkih za proizvodnjo sestavkov protitelesa proti IL12/IL23
|
|
WO2019212253A1
(fr)
|
2018-05-02 |
2019-11-07 |
사회복지법인 삼성생명공익재단 |
Anticorps se liant de manière spécifique à c-met et utilisation associée
|
|
EP3790866A4
(fr)
|
2018-05-08 |
2022-03-02 |
Janssen Sciences Ireland Unlimited Company |
Dérivés de dihydropyrimidine et leurs utilisations dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
|
|
JP2021523138A
(ja)
|
2018-05-11 |
2021-09-02 |
ヤンセン バイオテツク,インコーポレーテツド |
Il−23抗体を使用してうつを治療する方法
|
|
WO2019220368A1
(fr)
|
2018-05-16 |
2019-11-21 |
Janssen Biotech, Inc. |
Anticorps bispécifiques bcma/cd3 et gprdc5d/cd3 aux fins d'utilisation dans le traitement du cancer
|
|
WO2019220412A2
(fr)
|
2018-05-18 |
2019-11-21 |
Janssen Biotech, Inc. |
Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23
|
|
EP3569618A1
(fr)
|
2018-05-19 |
2019-11-20 |
Boehringer Ingelheim International GmbH |
Antagonisation d'anticorps cd73
|
|
US11525010B2
(en)
|
2018-05-23 |
2022-12-13 |
Pfizer Inc. |
Antibodies specific for GUCY2c and uses thereof
|
|
AU2019274654B2
(en)
|
2018-05-23 |
2023-07-20 |
Pfizer Inc. |
Antibodies specific for CD3 and uses thereof
|
|
BR112020023508A2
(pt)
|
2018-05-24 |
2021-03-30 |
Janssen Biotech, Inc. |
Anticorpos anti-cd3 e usos dos mesmos
|
|
JOP20190116A1
(ar)
|
2018-05-24 |
2019-11-24 |
Janssen Biotech Inc |
الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
|
|
US20210147532A1
(en)
|
2018-05-24 |
2021-05-20 |
Ares Trading S.A. |
Method for controlling the afucosylation level of a glycoprotein composition
|
|
MX2020012598A
(es)
|
2018-05-24 |
2021-05-27 |
Janssen Biotech Inc |
Agentes aglutinantes del psma y usos de estos.
|
|
WO2019231243A1
(fr)
|
2018-05-29 |
2019-12-05 |
사회복지법인 삼성생명공익재단 |
Cellule nourricière exprimant ox40l et procédé de culture de cellules tueuses naturelles l'utilisant
|
|
WO2019232110A1
(fr)
|
2018-05-30 |
2019-12-05 |
Mayne Pharma International Pty Ltd |
Inhibition de la voie hedgehog pour le traitement du carcinome basocellulaire à haut risque ou du syndrome de naevus du carcinome basocellulaire à haut risque
|
|
US20210235673A1
(en)
|
2018-06-05 |
2021-08-05 |
Samsung Life Public Welfare Foundation |
Graves' ophthalmopathy phenotype animal model, construction method therefor, and method for screening therapeutic material for graves' ophthalmopathy
|
|
CA3045370A1
(fr)
|
2018-06-08 |
2019-12-08 |
Pfizer Inc. |
Methodes de traitement de la maladie metabolique
|
|
TWI848953B
(zh)
|
2018-06-09 |
2024-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
|
CN119185533A
(zh)
|
2018-06-11 |
2024-12-27 |
耶鲁大学 |
新型免疫检查点抑制剂
|
|
GB201809699D0
(en)
|
2018-06-13 |
2018-08-01 |
Singapore Health Serv Pte Ltd |
IL-11 antibodies
|
|
GB201809700D0
(en)
|
2018-06-13 |
2018-08-01 |
Singapore Health Serv Pte Ltd |
IL-11 antibodies
|
|
AU2019289223B2
(en)
|
2018-06-18 |
2023-09-21 |
Janssen Pharmaceutica Nv |
Pyrazole derivatives as MALT1 inhibitors
|
|
EA202190055A1
(ru)
|
2018-06-18 |
2021-04-23 |
Янссен Фармацевтика Нв |
Производные пиразола в качестве ингибиторов malt1
|
|
EP3814326A4
(fr)
|
2018-06-26 |
2022-03-16 |
Janssen Sciences Ireland Unlimited Company |
Dérivés de dihydropyrimidine et leurs utilisations dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
|
|
SG11202012529VA
(en)
|
2018-06-27 |
2021-01-28 |
Boehringer Ingelheim Rcv Gmbh |
Means and methods for increased protein expression by use of transcription factors
|
|
WO2020006347A1
(fr)
|
2018-06-29 |
2020-01-02 |
Boehringer Ingelheim International Gmbh |
Anticorps anti-cd40 destinés à être utilisés dans le traitement d'une maladie auto-immune
|
|
WO2020016838A2
(fr)
|
2018-07-18 |
2020-01-23 |
Janssen Biotech, Inc. |
Prédicteurs de réponse prolongée après le traitement avec un anticorps spécifique anti-il23
|
|
US11053235B2
(en)
|
2018-08-09 |
2021-07-06 |
Janssen Sciences Ireland Unlimited Company |
Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
|
|
CN112912395B
(zh)
|
2018-08-20 |
2024-08-23 |
辉瑞公司 |
抗gdf15抗体、组合物和使用方法
|
|
US20200061015A1
(en)
|
2018-08-23 |
2020-02-27 |
Janssen Biotech, Inc. |
Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations
|
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
|
HUE061186T2
(hu)
|
2018-08-28 |
2023-06-28 |
Boehringer Ingelheim Int |
Heteroaromás vegyületek mint vanin-inhibitorok
|
|
EP3848388B1
(fr)
|
2018-09-05 |
2025-08-20 |
LG Chem, Ltd. |
Polypeptide de fusion comprenant une région polypeptidique pouvant être o-glycosylée
|
|
CN112823167B
(zh)
|
2018-09-07 |
2025-07-15 |
辉瑞大药厂 |
抗-αvβ8抗体和组合物及其用途
|